NEW YORK, Dec. 23 /PRNewswire/ -- Forest Laboratories, Inc. (AMEX: FRX), in response to a recent government report recommending antivirals be considered as a flu prevention alternative, announced today that it s prepared to meet potentially increased demands for its product Flumadine. Flumadine, an antivira1 medication
PR Newswire, Monday, December 23, 1996 8:33 AM EDT.
PHILADELPHIA, Dec. 23 /PRNewswire/ -- The following statement was issued today by The Philadelphia AIDS Consortium: A group of community leaders called for the Commonwealth of Pennsylvania to rescind a $12 million contract with Benova, Inc., the corporation hired to enroll a11 persons eligible for Medicaid in managed c
PR Newswire, Monday, December 23, 1996 - 9:00 AM EDT.
LA JOLLA, Calif., Dec. 23 /PRNewswire/ -- Agouron Pharmaceuticals Inc today announced it has submitted to the U.S. Food and Drug Administration ( FDA ) a New Drug Application (NDA) covering its anti-HIV drug VIRACEPT(R) (nelfinavir mesylate). Agouron is the first company to petition FDA for simultaneous approval of its
LONDON and FOSTER CITY, Calif., Dec. 20 /PRNewswire/ -- Pharmacia & Upjohn , Inc. (NYSE: PNU), and Gilead Sciences , Inc. (Nasdaq: GILD), announced today that the Committee for Proprietary Medicinal Products (CPMP) has recommended that Vistide (R) (cidofovir injection), an intravenous treatment for
DUBLIN, Ireland , Dec. 19 /PRNewswire/ -- Trinity Biotech (Nasdaq: TRIBY) today announced that it has submitted its Uni-Gold HIV test to the U.S. Food and Drug Administration ( FDA ). Trinity s Uni-Gold HIV test is a simple, easy to use, one-step test which has been submitted to the FDA for approva
SAN DIEGO, Dec. 19 /PRNewswire/ -- Allergan Ligand Retinoid Therapeutics, Inc. (ALRT) (Nasdaq: ALRIZ) today announced that it has received clearance from the Food and Drug Administration to launch Phase I/IIa clinical trials for the treatment of advanced cancers with ALRT1550 capsules, a new investigational anti-cancer
SAN MATEO, Calif., Dec. 19 /PRNewswire/ -- SciClone Pharmaceuticals, Inc., an international biopharmaceutical company, today reported that its lead product, ZADAXIN(R) thymosin alpha 1, achieved strong results in a hepatitis C trial led by Dr. Guido Rasi of the Institute of Experimental Medicine in Rome. A report on th
COLLEGEVILLE, Pa., Dec. 19 /PRNewswire/ -- NanoSystems LLC today announced an agreement with Merck & Co. , Inc. to collaborate on the evaluation of an experimental NanoCrystal(TM) formulation of Merck s HIV protease inhibitor, indinavir, for the treatment of HIV in pediatric patients and other special patient group
BOSTON, Dec. 18 /PRNewswire/ -- In a survey released today, researchers at CenterWatch found that consumers and patients unanimously voted against additional FDA review for clinical trials already approved for Internet listing by an Institutional Review Board (IRB). Survey respondents also said that the Internet is the
GAITHERSBURG, Md., Dec. 18 /PRNewswire/ -- IGEN International, Inc. (Nasdaq: IGEN) announced today that it has obtained worldwide rights to a novel immunoassay for detection and quantitation of human immunodeficiency virus (HIV-1) from the U.S. National Institutes of Health (NIH). IGEN intends to develop the test for c
LOS ANGELES, Dec. 18 /PRNewswire/ -- CARING FOR BABIES WITH AIDS, the only organization of its kind dedicated to providing residential, direct care and outreach services to HIV/AIDS affected children and families living in Los Angeles, has been selected by A / X ARMANI EXCHANGE of Santa Monica, CA as recipients of its
PITTSBURGH, Dec. 18 /PRNewswire/ -- Stadtlanders Pharmacy announced today the execution of a definitive agreement to purchase Castro Village Pharmacies, with locations in Los Angeles and San Francisco, from ValueRx. Stadtlanders is a provider of disease-specific pharmaceutical care to tens of thousands of individuals l
RICHMOND, Calif., December 18, 1996 -- Neurobiological Technologies, Inc. (Nasdaq: NTII) today announced that the Adult AIDS Clinical Trials Group (AACTG) has initiated a Phase II clinical trial of NTII s neuroprotectant Memantine, an orally administered NMDA receptor antagonist. The trial will evaluate Memantine s abi
ITHACA, N.Y., Dec. 12 /PRNewswire/ -- Paracelsian Inc today announced preliminary results of its initial human safety trial of AndroVir(TM) in HIV-positive subjects conducted by Bastyr University. Bastyr is a College of Natural Medicine (Naturopathy) located in Seattle, Washington, that studies natural products through
GAITHERSBURG, Md., Dec. 11 /PRNewswire/ -- MedImmune, Inc. (Nasdaq: MEDI) today announced it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration ( FDA ) to initiate human clinical trials with a vaccine for the prevention of human papillomavirus (HPV) disease of
NEW YORK, Dec. 10 /PRNewswire/ -- Advanced Viral Research Corp today announced preliminary results of a clinical trial of its peptide nucleic acid drug RETICULOSE in patients with AIDS. The double-blind, randomized, placebo-controlled clinical trial is being conducted at The Queen Elizabeth Hospital, University of the
SALT LAKE CITY, Dec. 10 /PRNewswire/ -- Medical Discoveries, Inc. (OTC Bulletin Board: MLSC) today announced successful test results evaluating the potential of its proprietary multipurpose antimicrobial agent, MDI-P (Medical Discoveries Inc.(Pharmaceutical), against Candida albicans, a pathogenic yeast/fungus, that co
SAN DIEGO, Dec. 9 /PRNewswire/ -- Debra Breneman, MD, Associate Professor of Clinical Dermatology and Director of Dermatopharmacology at the University of Cincinnati, today reported to the medical scientific community at the American Society of Hematology Conference, interim results of Phase I/II clinical trials for th
ORLANDO, Dec. 9 /PRNewswire/ -- IDEC Pharmaceuticals Corporation (Nasdaq: IDPH) and Genentech , Inc. (NYSE: GNE) have announced positive final results from a pivotal Phase III trial of IDEC-C2B8 as a single agent therapy for relapsed low grade or follicular non-Hodgkin s lymphoma . The trial, conducted in a to
NEW YORK, Dec. 9 /PRNewswire/ -- In an unscheduled visit, Elizabeth Taylor dropped in to visit staff and clients of the Lower East Side Harm Reduction Center on Thursday, December 5 in Manhattan. Together with hairdresser Jose Eber and Joe Spellman, the Executive Vice President for Elizabeth Arden, the actress arrived
PHILADELPHIA, Dec. 6 /PRNewswire/ -- Philadelphia AIDS Consortium Executive Director Larry Hochendoner announced today that he and Board President Joe Cronauer (Executive Director of We the People Living with HIV/AIDS) invited the Executive Directors of AIDS service organizations to join them on Tuesday, December 10 at
PR Newswire, Thursday December 5 1996 - 9:27 AM EDT
MIAMI, Dec. 5 /PRNewswire/ -- AIDS Services of Dallas, a Dallas nonprofit housing developer, is among six community-based nonprofits to receive the first Metropolitan Life Foundation Award for Excellence in Affordable Housing in the category of supportive housing. The $15,000 award, will be presented at The Enterprise
PR Newswire, Wednesday December 4 1996 - 5:18 PM EDT
SAN FRANCISCO--(BUSINESS WIRE)--Dec. 4, 1996--Peter Duesberg Website Launch Dec. 9, 1996, 10:00 a.m. INTERNET alfredo. 790-A Brannan Street, San Francisco Peter Duesberg, Berkeley biologist-errant, who enraged AMA officials by opposing the belief that HIV causes AIDS, will be on hand at INTERNET alfredo for the launch
SAN MATEO, Calif., Dec. 4 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN), an international biopharmaceutical company, announced today that it has launched ZADAXIN(R) thymosin alpha 1 in the People s Republic of China as a treatment for chronic hepatitis B. The launch commenced after clinical data from th
PALO ALTO, Calif., Dec. 4 /PRNewswire/ -- SyStemix, Inc. (Nasdaq: STMX) today announced that the FDA has accepted SyStemix Investigational New Drug (IND) application to initiate a Phase I/II gene therapy trial for treatment of HIV-infected patients. According to the trial protocol, a therapeutic gene (Rev M10) will be
MADISON, N.J., Dec. 4 /PRNewswire/ -- Schering Corporation, a subsidiary of Schering-Plough Corporation (NYSE: SGP) has filed suit against Amgen Inc. of Thousand Oaks, Calif., charging that Amgen s manufacture and use of its consensus interferon product INFERGEN infringes U.S. Patent No. 4,530,901 held by Biogen Inc.
PHILADELPHIA, Dec. 3 /PRNewswire/ -- Today, the City of Philadelphia s Health Department and Mercy Health Corporation of Southeastern Pennsylvania, announced that the West Mt. Airy personal care home for persons living with AIDS is no longer able to accept admissions in order to eventually close the personal care home.
SAN DIEGO, Dec. 3 /PRNewswire/ -- Priority Pharmacy, a leading source of HIV- and AIDS-related medications and information, has been chosen as one of six nationwide distributors of the new breakthrough AIDS drug Serostim(TM), announced David C. Zeiger, president and CEO of the nationwide home-delivery pharmacy that in
NORWELL, Mass., Dec. 2 /PRNewswire/ -- The SeroCare(TM) Program, a comprehensive assistance package to benefit both physicians and people with AIDS wasting, was launched today by Serono Laboratories, Inc. SeroCare includes a unique cost containment program, a national network of specialty pharmacy distributors, reimbur
PR Newswire, Monday, 2 December 1996, 8:31 A.M. EDT
CHICAGO, Dec. 2 /PRNewswire/ -- The Female Health Co announced that it has signed a three-year agreement with the Joint United Nations Programme on HIV/AIDS ( UNAIDS ) to provide a global public sector price for the female condom. The agreement, based on worldwide demand, enables each of the program s 160 U.N. member s
CARLSBAD, Calif., Dec. 2 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) has demonstrated that antisense compounds can work through a novel mechanism of RNA splicing, inhibiting a key step in RNA metabolism and the production of disease-causing proteins. In an article published in the November 29, 1996 issue of Jo
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 29 November 1996.
SEATTLE, Nov. 29 /PRNewswire/ -- PATH (Program for Appropriate Technology in Health), an international, nonprofit organization headquartered in Seattle, has developed a unique computer program designed to help teach condom use. The software, How To Use A Condom Correctly, runs on a 386 or faster PC and is designed to g
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 28 November 1996, 6 A.M. EST
ADVANCE/ LONDON, Nov. 28 /PRNewswire/ -- The Female Health Co today announced that it has signed a three-year agreement with the Joint United Nations Programme on HIV/AIDS ( UNAIDS ) to provide a global public sector price for the female condom. The agreement, based on worldwide demand, enables each of the program s 19
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 27 November 1996 5:43 PM EDT
WASHINGTON, Nov. 27 /PRNewswire/ -- On Sunday, December 1, the White House will dim its lights for fifteen minutes, between 7:45 and 8:00 p.m., to observe World AIDS Day and to offer a tribute to those infected and affected by HIV/AIDS. Villages, towns and cities across the country will join the White House as a visual
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 26 November 1996.
WASHINGTON, Nov. 26 /PRNewswire/ -- The Department of Veterans Affairs (VA) health care system, the nation s single largest source of direct care to AIDS and HIV-infected patients, has advanced clinical care and treatment of this population by integrating research with patient care. Veterans with HIV infection receive
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 25 November 1996 11:25 AM EDT
WAKE FOREST, N.C., Nov. 25 /PRNewswire/ -- Although it may not make the daily headlines anymore, the AIDS crisis is not going away. It is estimated that by the year 2000, 110 million people will be infected by HIV, the virus that causes AIDS*. And there is still no cure in sight. What can we do to stop the spread of AI
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 25 November 1996 10:03 AM EDT
CHICAGO, Nov. 25 /PRNewswire/ -- God s Love We Deliver (GLWD), a meal-delivery service for New York City-area residents who are confined to their homes by AIDS-related illnesses, will receive the 1996 Sara Lee Foundation Leadership award, Michael E. Murphy, Sara Lee Foundation president, announced today. A presentation
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 25 November 1996 - 8:03 A.M.
LOS ANGELES, Nov. 25 /PRNewswire/ -- In keeping with its leadership role on issues pertaining to pediatric HIV/AIDS, the Pediatric AIDS Foundation announces concurrent with World AIDS Day, December 1, the funding of The Fernwood Project, a national demonstration project for youth HIV education and prevention. The progr
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 20 November 1996.
NEW YORK, Nov. 20 /PRNewswire/ -- Author Elinor Burkett, in her book The Gravest Show On Earth: America In The Age Of Aids, published by Picador, is scathing in her criticism of all the major players in the AIDS crisis, including politicians, the scientists, the drug companies, the gay activists, and the black communit
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 20 November 1996.
FERNDALE, Mich., Nov. 20 /PRNewswire/ -- The Midwest AIDS Prevention Project (MAPP) is proud to present INFINITY, the new symbol of hope in the fight against the spread of HIV/AIDS. This one of a kind jewelry emblem can only be described as a masterpiece. Its intricate design and symbolism breathe new life into the str
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 20 November 1996.
WASHINGTON, Nov. 20 /PRNewswire/ -- Planned Parenthood Federation of America President Gloria Feldt announced today that the nationally-known family planning organization applauds and strongly supports the recommendations of the Institute of Medicine to launch an aggressive campaign to fight sexually transmitted infect
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 19 November 1996.
WASHINGTON, Nov. 19 /PRNewswire/ -- Unimed Pharmaceuticals, Inc. (Nasdaq: UMED) today announced that results of a preliminary study, suggesting Marinol(R) (dronabinol) may be useful in the treatment of anorexia as well as disturbed behavior and mood in geriatric patients with Alzheimer s disease, were presented here at
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 19 November 1996.
MOUNTAIN VIEW, Calif., Nov. 19 /PR Newswire/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI) today announced that Boehringer Mannheim GmbH, a collaborative partner of the Company, has initiated a multinational Phase II clinical trial of PDL s Human Anti-Hepatitis B Antibody in patients with chronic hepatitis B infect
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 19 November 1996.
MOUNTAIN VIEW, Calif., Nov. 19 /PR Newswire/ -- Protein Design Labs, Inc. (PDL) today announced that Boehringer Mannheim GmbH, a collaborative partner of the Company, has initiated a multinational Phase II clinical trial of PDL s Human Anti-Hepatitis B Antibody in patients with chronic hepatitis B infection. This study
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 18 November 1996.
LOS ANGELES, Nov. 18 /PRNewswire/ -- Edward Gomperts, M.D., a researcher at Childrens Hospital Los Angeles (CHLA), was one of several co-authors of an article recently published by the prestigious journal Science. The study titled Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of th
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 18 November 1996.
WHO: Dr. Scmakula Kiwanuka, Ambassador of Uganda to the United Nations, Dr. Helen Gayle, Director of the Center for HIV, STD, and TB Prevention at the Centers for Disease Control and Prevention, Umberto Cruz, Director of the Division of HIV Health and Community Services at the AIDS Institute, and Ronald Johnson,
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 13 November 1996.
CAMBRIDGE, Mass., Nov. 13 /PRNewswire/ -- Before the AIDS virus can invade a cell, it must pair with a first receptor, then change shape to expose a second structure that binds to a second receptor, it was reported in the November 14 issue of Nature. This discovery, by scientists at LeukoSite, Inc. (Cambridge, Mass.),
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 13 November 1996.
PHILADELPHIA, Nov. 13 /PRNewswire/ -- The Philadelphia AIDS Consortium issued the following: An estimated 60 percent of people living with HIV/AIDS in the region currently rely on Medical Assistance for their healthcare. A broad coalition of people with HIV/AIDS, AIDS service organizations and advocates (see list below
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 13 November 1996
ALEXANDRIA, Va., Nov. 13 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq: CELI) announces today that the Japanese Patent Office has issued a patent on the diagnostic use of CEL-SCI s HGP-30 technology in AIDS. Japan constitutes one of the largest pharmaceutical markets in the world and is a major gateway into Asia, an area
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 12 November 1996.
SAN MATEO, Calif., Nov. 12 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN), reported today that the results of its 103 patient randomized, double-blind and placebo-controlled U.S. chronic hepatitis C trial were presented by the principal investigator, Kenneth Sherman, M.D., Ph.D., of the University of Cin
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 12 November 1996.
BUFFALO GROVE, Ill., Nov. 12 /PRNewswire/ -- Unimed Pharmaceuticals, Inc. (Nasdaq: UMED) today announced that the AIDS Clinical Trials Group (ACTG), a cooperative supported by the National Institute of Allergy and Infectious Diseases, will conduct a Phase II/III placebo controlled study of nitazoxanide (NTZ) to treat A
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 12 November 1996.
THE WOODLANDS, Texas, Nov. 12 /PRNewswire/ -- Aronex Pharmaceuticals, Inc. (Nasdaq/NNM: ARNX) today reported preliminary results from Phase I trials of Zintevir(TM), the first of a new class of HIV integrase inhibiting compounds, in HIV-positive patients. Based upon these results, Aronex is planning follow-on multiple
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Saturday, 11 November 1996.
CHICAGO, Nov. 11 /PRNewswire/ -- Results from a large, multi-national, dose finding study show that the antiviral agent Famvir(R) (famciclovir, SmithKline Beecham) is effective in the treatment of chronic hepatitis B with a safety profile comparable to placebo. The study provides clear evidence that famciclovir acts qu
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday 11 November 1996.
WARREN, N.J., Nov. 11 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) today reconfirmed that it will submit a New Drug Application (NDA) by the end of 1996 with the Food and Drug Administration for the use of thalidomide in the treatment of erythema nodosum leprosem (ENL), a disorder associated with leprosy. The
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 8 November 1996.
AMSTERDAM, The Netherlands , Nov. 8 /PRNewswire/ -- QIAGEN N.V., (Nasdaq: QGENF) today announced it has acquired a technology platform for DNA and RNA purification and stabilization of samples such as clinical specimens using cationic detergents, from the Iowa Biotechnology Corporation and the University of Iowa. Under
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 6 November 1996.
BUFFALO GROVE, Ill., Nov. 6 /PRNewswire/ -- Unimed Pharmaceuticals, Inc. (Nasdaq: UMED) today announced that, despite the passage of proposition 215 to make marijuana legal for medicinal purposes in California and a similar proposal in Arizona, a pure synthetic formulation of marijuana s active ingredient THC is availa
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 6 November 1996.
MINNEAPOLIS, Nov. 6 /PRNewswire/ -- INCSTAR Corporation announced today that it has received 510(k) clearance to market its second generation tests for the detection of the infectious diseases, rubella, cytomegalovirus ( CMV ) and herpes simplex. These products have been marketed in Europe for several years through the
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 5 November 1996.
SAN DIEGO, Nov. 5 /PRNewswire/ -- Researchers published three studies in the current issue of the journal Science (vol. 274, issue 5288) that for the first time show how tumor cells survive and adapt to chemotherapy. Cells die by a process called apoptosis, or programmed cell death, which can be induced by agents such
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 4 November 1996.
CHICAGO, Nov. 4 /PRNewswire/ -- AIDS, future employment prospects, education and the current political process are the top concerns of Midwest high school students, according to results disclosed today of the Ameritech Long Distance LearningLink Student Survey. The survey was conducted among 2,857 students at four high
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 4 November 1996.
DETROIT, Nov. 4 /PRNewswire/ -- AIDS Partnership Michigan is pleased to announce the launch of Michigan s first hot-meal home delivery program for homebound people with AIDS. The program, which began delivering meals on Monday, October 21, 1996, will initially focus on the areas of metro Detroit with the highest concen
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 4 November 1996.
DEERFIELD, Ill., Nov. 4 /PRNewswire/ -- Fujisawa USA , Inc. and Roxane Laboratories Inc. announced today that Roxane has acquired the NDA and all rights to Duraclon(TM) (clonidine HCl), a new treatment for severe pain in cancer patients. The FDA has granted marketing clearance of Dura
NUTLEY, N.J., Dec. 3 /PRNewswire/ -- Hoffmann-La Roche announced today that the company has received clearance from the Food and Drug Administration ( FDA ) to market oral ganciclovir (Cytovene(R) capsules) for the prevention of cytomegalovirus ( CMV
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 1 November 1996
CAMBRIDGE, Mass., Nov. 1 /PRNewswire/ -- Researchers from Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) have solved the three-dimensional atomic structure of p38 mitogen-activated protein (MAP) kinase, a human enzyme that regulates key cytokines involved with inflammation and programmed cell death. The discovery i
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 31 October 1996.
ALEXANDRIA, Va., Oct. 31 /PRNewswire/ -- In response to multiple investor inquiries, CEL-SCI CORPORATION (Nasdaq: CELI) announces interim results of its Phase I safety study with the HGP-30 AIDS vaccine in HIV infected individuals. AIDS ReSearch Alliance, a non-profit AIDS research organization located in West Hollywoo
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 31 October 1996.
CARLSBAD, Calif., Oct. 31 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that the Ministry of Health of the Autonomous Government of Madrid, Spain will be conducting a Phase II combination therapy clinical trial using REMUNE and antiviral drugs for the treatment of HIV infection. The thr
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 31 October 1996.
CAMBRIDGE, Mass., Oct. 31 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN) today announced that the House of Lords in the United Kingdom has ruled that one of its two British patents for hepatitis B antigens is invalid. The decision of the House of Lords affirms an October 1994 ruling of the United Kingdom s Court of Appeal
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 31 October 1996
CARLSBAD, Calif., Oct. 31 /PRNewswire/ -- The Immune Response Corporation announced today that the Ministry of Health of the Autonomous Government of Madrid, Spain will be conducting a Phase II combination therapy clinical trial using REMUNE and antiviral drugs for the treatment of HIV infection. The three year Phase
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 29 October 1996.
CHICAGO, Oct. 29 /PRNewswire/ -- With the goal of integrating balanced, accurate information about the female condom throughout all levels of safer sex education, a working group comprising public health professionals from the U.S. and the U.K. met for the second time on Oct. 21-22. The Scientific Advisory Group on Edu
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 29 October 1996.
SANTA MONICA, Calif., Oct. 28 /PRNewswire/ -- The Pediatric AIDS Foundation announced today that its Co-Founder and Chief Executive Officer Susan DeLaurentis has been invited to serve on the Office of AIDS Research Advisory Council (OARAC), National Institutes of Health, for a two-year term. The invitation came directl
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Thursday, 24 October 1996.
LA JOLLA, Calif., Oct. 24 /PRNewswire/ -- Agouron Pharmaceuticals, Inc., today announced that it will proceed promptly to assemble and file with the U.S. Food and Drug Administration ( FDA ) a New Drug Application (NDA) seeking approval to commence marketing of the company s HIV protease inhibitor VIRACEPT(TM) (nelfina
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 23 October 1996
WASHINGTON, Oct. 23 /PRNewswire/ -- A nationwide search has been launched to identify young people who have chosen to become involved in the fight against AIDS, and who exemplify the highest standards of volunteerism and community service as a result of their involvement. Twenty young people between the ages of 12 and
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 18 October 1996
LA JOLLA, Calif., Oct. 18 /PRNewswire/ -- Agouron Pharmaceuticals, Inc., today announced that its scientists have solved the three- dimensional atomic structure of the protease enzyme encoded by the human hepatitis C virus (HCV). HCV is a virus that causes illness that ranges from a mild flu-like disease to progressive
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 21 October 1996
MOUNTAIN VIEW, Calif., Oct. 21 /PRNewswire/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI) announced today that it has signed an agreement to humanize a mouse monoclonal antibody for a Japanese company. Under the terms of the agreement, the Japanese company will have a non-exclusive license under PDL s patents relat
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 18 October 1996.
CAMBRIDGE, Mass., Oct. 18 /PRNewswire/ -- Researchers from Vertex Pharmaceuticals Incorporated have solved the three-dimensional atomic structure of the hepatitis C virus NS3 protease, an enzyme that plays a key role in viral replication. The achievement is described in a paper, Crystal Structure of the Hepatitis C Vir
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 15 October 1996.
SAN MATEO, Calif., Oct. 15 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN), an international biopharmaceutical company, reported today that its lead product, thymosin alpha 1, achieved statistically significant results in the treatment of chronic hepatitis B in a multicenter, randomized and controlled stu
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 15 October 1996
ORLANDO, Fla., Oct. 15 /PRNewswire/ -- More than 500 fabric panels from the AIDS Memorial Quilt will soon be on public display at Universal Studios Florida. Representing AIDS victims from the southeastern U.S., the quilt display at Universal is in recognition of World AIDS Day on December 1 and follows the October 11-1
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 14 October 1996
CARLSBAD, Calif., Oct. 14 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that the Food and Drug Administration ( FDA ) has granted allowance for an expanded access program to satisfy the increasing level of patient demand for REMUNE. The expanded access program is designed to provide REM
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 8 October 1996
WARREN, N.J., Oct. 8 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) announced successful completion of its pivotal Phase II/III clinical trial of Synovir(R) (thalidomide) for severe weight loss (cachexia) associated with HIV infection, the virus which causes AIDS. The company anticipates that it will announce resul
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 8 October 1996
LAS VEGAS, Oct. 8 /PRNewswire/ -- Famciclovir (Famvir(R), SmithKline Beecham) is safe, well-tolerated and effective in significantly suppressing herpes simplex virus-2 (HSV-2) outbreaks among HIV-infected individuals, according to a recent study conducted at the University of Washington. In the first phase of the study
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 8 October 1996
WARREN, N.J., Oct. 8 /PRNewswire/ -- Celgene Corporation announced successful completion of its pivotal Phase II/III clinical trial of Synovir (thalidomide) for severe weight loss (cachexia) associated with HIV infection, the virus which causes AIDS. The Company anticipates that it will announce results of the trial ea
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 8 October 1996
LAS VEGAS, Oct. 8 /PRNewswire/ -- Famciclovir (Famvir(R), SmithKline Beecham) is safe, well-tolerated and effective in significantly suppressing herpes simplex virus-2 (HSV-2) outbreaks among HIV-infected individuals, according to a recent study conducted at the University of Washington. In the first phase of the study
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 8 October 1996
CARLSBAD, Calif., Oct. 8 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it has agreed to develop and distribute REMUNE in South America and Central America through Viru-Tech Limited ( Viru- Tech ), a privately held company. Under the agreement, Viru-Tech has purchased $3 million of
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 7
WASHINGTON, Oct. 7 /PRNewswire/ -- Many of you will recognize Eric Slocum as news anchor and reporter at KOMO TV in Seattle. Slocum is also a poet with a dream of giving hope to children with AIDS. He has accomplished this by generously offering 100% of the proceeds of the sale of his book, New Words to support pediatr
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 7 October 1996
SHREVEPORT, La., Oct. 7 /PRNewswire/ -- A joint effort between scientists and industry has resulted in the development of a new drug to treat patients in the advanced stages of AIDS. The drug, HRG214, was invented by Dr. Frank Gelder, director of Immunodiagnostic Testing Laboratories, Department of Surgery at Louisiana
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 4 October 1996
PHILADELPHIA, Oct. 4 /PRNewswire/ -- SmithKline Beecham, distributor of Engerix-B(R) (Hepatitis B Vaccine, Recombinant), today announced that it has been awarded the hepatitis B adult vaccine contract by the U.S. Centers for Disease Control and Prevention (CDC). Hepatitis B is one of the most common preventable infecti
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 4 October 1996
WASHINGTON, Oct. 4 /PRNewswire/ -- From defending marriage to fighting for the lives of children killed late in pregnancy to presenting an unprecedented balanced budget with pro-family tax relief, the 104th Congress took historic steps for America s families, said Family Research Council President Gary L. Bauer on Frid
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 4 October 1996
WEST POINT, Pa., Oct. 4 /PRNewswire/ -- Comvax(TM) (Haemophilus b conjugate (meningococcal protein conjugate) and Hepatitis B (recombinant) vaccine) has been licensed by the U.S. Food & Drug Administration ( FDA ). Developed by Merck & Co. , Inc., it is the first combination product indicated for vaccination of
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 4 October 1996
WEST POINT, Pa., Oct. 4 /PRNewswire/ -- The following was released today by Merck & Co. Inc.: DESCRIPTION COMVAX(TM)* (Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine) is a sterile bivalent vaccine made of the antigenic components used in producing PedvaxHIB(R) (Haemo
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Friday, 4 October 1996
WEST POINT, Pa., Oct. 4 /PRNewswire/ -- Comvax(TM) (Haemophilus b conjugate (meningococcal protein conjugate) and Hepatitis B (recombinant) vaccine) has been licensed by the U.S. Food & Drug Administration ( FDA ). Developed by Merck & Co. , Inc. (NYSE: MRK), it is the first combination product indicated for va
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 2 October 1996
WASHINGTON, Oct. 2 /PRNewswire/ -- Citing the continuing rise in infectious disease statistics throughout the world, Novatek International Inc. s (Nasdaq: NVT) principals outlined the company s tremendous growth potential as exclusive licensees to market and distribute rapid result diagnostic test devices manufactured
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 2 October 1996
SAN MATEO, Calif., Oct. 2 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) reported today publication of an abstract by the principal investigator of its U.S. randomized, double-blind placebo controlled chronic hepatitis C trial. The abstract reports that the combination of ZADAXIN and alpha interferon dem
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 2 October 1996
LONDONDERRY, N.H., Oct. 2 /PRNewswire/ -- Diatide, Inc. (Nasdaq: DITI), which is engaged in developing proprietary radiopharmaceuticals for use in nuclear medicine procedures, has begun Phase II clinical trials of its P483H Techtide, which is intended to provide a new, more effective and safer method of imaging the exa
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 1 October 1996
ALEXANDRIA, Va., Oct. 1 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq: CELI) and NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE today announce that they have signed a Collaborative Research Agreement to jointly identify and evaluate Herpes Simplex Virus related peptides. This agreement may lead to the future developm
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 1 October 1996
FAIRFAX, Va., Oct. 1 /PRNewswire/ -- The American Society of Cataract and Refractive Surgery (ASCRS) announced today that the spending bill passed by the U.S. Senate last night and signed into law by President Clinton provides relief for health care practitioners from the threat of legal action for performing patented
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 1 October 1996
CARLSBAD, Calif., Oct. 1 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR), announced today that the United States Patent Office has issued a Notice of Allowance to the Sidney Kimmel Cancer Center ( SKCC ) on a cancer treatment licensed exclusively to Immune Response. The allowed application is entitled Ly
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
PHILADELPHIA, Sept. 23 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) (SB) has received approval through the new centralized European registration procedure to market Twinrix, the first combined vaccine against hepatitis A (HAV) and B (HBV). The approval applies to all 15 countries in the European Union. HAV and HBV af
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Monday, 30 September 1996
NORCROSS, Ga., Sept. 30 /PRNewswire/ -- Immucor, Inc. (Nasdaq: BLUD), maker of blood bank reagent systems and related products, announced today clinical trials for the Company s second automated blood analyzer, the ABS(HV), have begun. Like Immucor s leading instrument, the ABS2000, which was submitted previously to
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 30 Sep 1996
TARRYTOWN, N.Y., Sept. 30 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. today announced the publication of a scientific paper on Progenics proprietary HIV assay system, ProSys, in the September issue of the Journal of Virology (vol. 17, no. 9). The ProSys system models the earliest steps of the viral life cycle. Prog
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, Sept. 26 /PRNewswire/ -- As a result of tests run by Novatek International, Inc., the province of Corrientes, Argentina has directed its pharmaceutical company to expedite its agreement with Novatek to manufacture and distribute Novatek s rapid result whole blood diagnostic HIV tests there. A comparison
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
BOCA RATON, Fla., Sept. 27 /PRNewswire/ -- NABI (Nasdaq: NABI) announced today it has received a Japanese patent (Japanese Patent No. 2063902) for HIV- IG(TM), the Company s proprietary HIV immunotherapeutic, as well as the method of producing it. HIV-IG(TM) is one of NABI s lead immunotherapeutic products in developme
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, Sept. 26 /PRNewswire/ -- The Food and Drug Administration and the National Institutes of Health today announced measures designed to protect individuals who may benefit from emergency research. The FDA issued final rules to make it easier for promising experimental drugs and medical devices to be studied in
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
BETHLEHEM, Pa., Sept. 25 /PRNewswire/ -- STC Technologies, Inc., a leader in the development of detection technology, today announced a strategic partnership with Centocor Inc. (Nasdaq: CNTO), of Malvern, PA, to provide infectious disease screening kits to blood banks and plasma centers in the
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CARLSBAD, Calif., Sept. 24 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) published the results of clinical trials using REMUNE in combination with antiviral drug therapy to treat HIV infection in the September issue of the Journal of Clinical Immunology. These trials involved a total of 92 HIV-infected
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CHICAGO, Sept. 24 /PRNewswire/ -- The Female Health Company (AMEX: FHC) announced that UNAIDS (in consultation with its relevant partners, WHO, UNFPA, World Bank, USAID, the European Commission and others) in a letter to 193 country affiliates has solicited interest in and requested intended purchase volume for the fem
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
DUBLIN, Ireland , Sept. 24 /PRNewswire/ -- Trinity Biotech (Nasdaq: TRIBY) today announced the launch of Adenovirus and Rotavirus, two new laboratory based products which detect intestinal related viruses. Trinity has won supply contracts for these products in the United Kingdom ,
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, Sept. 24 /PRNewswire/ -- Family Research Council released Tuesday the 1996 Moms and Dad s School Survival Guide, a 64-page resource to help parents stay informed and involved in their children s educational process. Parents today are spending too much time combating condoms, offensive curriculum, and failed
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, Sept. 20 /PRNewswire/ -- The Department of Health and Human Services today proposed a new draft guideline for xenotransplantation -- the transplantation of animal organs and tissue into humans -- aimed at reducing the public health risks while not impeding medical innovation. The recommended procedures anno
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NEW ORLEANS, Sept. 18 /PRNewswire/ -- Results from a recent preclinical study showed that famciclovir (Famvir(R) SmithKline Beecham) is more effective than valacyclovir (Valtrex(R), Glaxo Wellcome ) in preventing recurrence of the Herpes Simplex Virus-Type 1 (HSV-1) after completion of treatment in immunosuppressed mic
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
LOS ANGELES, Calif., Sept. 18 /PRNewswire/ -- A compelling yellow eye debuts on a new 9-story high billboard on Friday morning, September 20, to warn Southern Californians that five million Americans have hepatitis and asks do you? The billboard is meant to attract attention to the life-threatening dangers of hepatitis
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
PHILADELPHIA, Sept. 18 /PRNewswire/ -- Scientists from SmithKline Beecham (NYSE: SBH) (SB) have published in the Sept. 19 issue of Nature the three- dimensional atomic structure of an enzyme required for replication of human cytomegalovirus .(1) The research underlying the publication advances efforts to discover new t
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CARLSBAD, Calif., Sept. 17 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today the first interim analysis of the Phase II clinical trial with REMUNE, which is being conducted in Thailand by Trinity Medical Group Co., Ltd. ( Trinity ). This portion of the Phase II trial involved 30 HIV-infecte
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CARLSBAD, Calif., Sept. 17 /PRNewswire/ -- The Immune Response Corporation announced today the first interim analysis of the Phase II clinical trial with REMUNE, which is being conducted in Thailand by Trinity Medical Group Co., Ltd. ( Trinity ). This portion of the Phase II trial involved 30 HIV-infected individuals,
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NEW ORLEANS, Sept. 16 /PRNewswire/ -- Oral ganciclovir (Cytovene(R) capsules), taken for fourteen weeks as preventive therapy, reduced the incidence of potentially life-threatening cytomegalovirus ( CMV ) disease by 79 percent in liver transplant recipients, according to data presented today at the Interscience Confere
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NEW ORLEANS, Sept. 16 /PRNewswire/ -- Unless swift action is taken, antibiotic-resistant bacteria will become an increasing issue in U.S. hospitals and communities, according to experts presenting at a satellite symposium prior to the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Resear
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NEW ORLEANS, Sept. 16 /PRNewswire/ -- The investigational HIV protease inhibitor 141W94 (VX-478) appears to have significant antiviral activity while also being well-tolerated, according to preliminary data from a small Phase I/II study presented today. 141W94 (VX-478) was discovered at Vertex Pharmaceuticals and is be
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
C O R R E C T I O N -- DuPont Merck In First Clinical Data Presented on An Investigational HIV Non- Nucleoside Reverse, moved Monday, September 16, we are advised by the company that the third graph, second line, should read 200 mg, led to a reduction in mean plasma HIV-RNA levels of -1.68 logs + or - 0.50 rather than
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NEW ORLEANS, La., Sept. 16 /PRNewswire/ -- A 54 percent reduction in the rate of HIV disease progression or death was observed in patients who added Epivir (R) (lamivudine; 3TC ), rather than adding placebo, to their current treatment regimen, according to a preliminary analysis of clinical tria
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NEW ORLEANS, Sept. 16 /PRNewswire/ -- HIV viral load was reduced by 99.9 percent (2.97 logs) with a combination of two protease inhibitors , Abbott Laboratories (NYSE: ABT) Norvir (TM) ( ritonavir ) and Hoffmann-La Roche s
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
GULPH MILLS, Pa., Sept. 16 /PRNewswire/ -- BTG plc (BTG) announced today that it has signed an exclusive worldwide license agreement with GenVec Inc. (GenVec), Rockville, MD, for the development of gene delivery systems based on BTG s Herpes simplex virus (HSV) technology. GenVec will develop HSV-based systems for the
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NEW ORLEANS, Sept. 16 /PRNewswire/ -- The investigational HIV protease inhibitor 141W94 (VX-478) appears to have significant antiviral activity while also being well-tolerated, according to preliminary data from a small Phase I/II study presented today. 141W94 (VX-478) was discovered at Vertex Pharmaceuticals and is be
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
LA JOLLA, Calif., Sept. 16 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. (Nasdaq-NNM: AGPH) today announced the availability of VIRACEPT(TM) (nelfinavir mesylate), an HIV protease inhibitor, through an expanded access program for people with advanced HIV disease who have exhausted all current protease inhibitor treatme
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NEW YORK, Sept. 13 /PRNewswire/ -- Virologix Corporation announced today that its vaccine candidate for human T cell leukemia virus type II (HTLV-II) was completely effective in animal studies. The results were presented in Baltimore by Dr. William W. Hall at the Annual Meeting of Tumor Cell Biology organized by the In
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CAMBRIDGE, Mass., Sept. 12 /PRNewswire/ -- The AIDS Clinical Trials Group (ACTG), a cooperative group supported by the National Institute of Allergy and Infectious Diseases, will conduct a 24-week Phase II monotherapy study of 141W94/VX-478, an HIV protease inhibitor being developed by Vertex Pharmaceuticals Incorporat
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
SAN FRANCISCO, Sept., 12 /PRNewswire/ -- Opportunistic infections of the orbits, or bony sockets that contain the eye globes, result in significant morbidity and mortality, and treatment should be initiated without delay, according to a study in Ophthalmology. Jan W. Kronish, MD, and colleagues from Florida reviewed th
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
ROCKVILLE, Md., Sept. 11 /PRNewswire/ -- Novavax, Inc. (AMEX: NOX) today reported completion of preclinical testing of testosterone and progesterone in its Micellar nanoparticle ( MNP ) transdermal drug delivery platform. A company spokesman said that peak blood levels of testosterone were approximately three times hig
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
MINNEAPOLIS, Sept. 6 /PRNewswire/ -- Recent media reports, including a USA TODAY article from August 30, 1996, indicate that salmonella poisoning from eggs is on the rise. The federal Centers for Disease Control and Prevention indicated last week that egg transmission has become the most common type of salmonella infec
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
LA JOLLA, Calif., Sept. 6 /PRNewswire/ -- Agouron Pharmaceuticals, Inc., today announced that its scientists have solved the three-dimensional atomic structure of the protease enzyme encoded by the human cytomegalovirus ( CMV ). A member of the family of herpes viruses, CMV causes degene
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
HALLANDALE, Fla., Sept. 4 /PRNewswire/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) of Hallandale, FL. has received in writing that a double blind clinical AIDS trial assessing the efficacy of the drug Reticulose in human patients with AIDS is currently underway. The study is taking place at the School o
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, Sep. 3 /PRNewswire/ -- The Food and Drug Administration is announcing a nationwide alert concerning 30 milliliter Vials of Hallmark Labs injectable adrenal cortex extract, distributed by Phyne Pharmaceuticals of Scottsdale, Ariz., because this product can cause serious and life-threatening injuries. Since A
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
PHILADELPHIA, Aug. 30 /PRNewswire/ -- Starting on August 21, thousands of claim forms were mailed to persons with hemophilia who were infected by the AIDS virus, pursuant to the terms of a proposed class action settlement approved by The Honorable John F. Grady, Judge of the United States District Court for the Nort
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
OMAHA, Neb., Aug. 28 /PRNewswire/ -- Researchers at the University of Nebraska Medical Center (UNMC) in Omaha have created the first comprehensive small animal model for HIV dementia , a breakthrough that will enable first- time testing of anti-HIV compounds for their ability to penetrate the blood- brain barrier and e
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
HALLANDALE, Fla., August 28 /PRNewswire/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) of Hallandale, Florida announces that a paper entitled Peptide Nucleic Acids Stimulate Gamma Interferon and Inhibit Replication of the Human Immunodeficiency Virus written by Shalom Z. Hirschman M.D., Professor of Medic
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
ABBOTT PARK, Ill., Aug. 27 /PRNewswire/ -- The European Commission, in Brussels, has granted final marketing authorization for Abbott Laboratories protease inhibitor Norvir ( ritonavir ) for treatment of human immunodeficiency virus (HIV) infection and AIDS.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
RICHMOND, Calif., Aug. 26 /PRNewswire/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) today announced that the company has initiated human clinical trials for Memantine, an orally available NMDA receptor antagonist. Excessive activation of the NMDA receptor on nerve cells plays an important role in producing symp
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, Aug. 26 /PRNewswire/ -- The National Association of People with AIDS (NAPWA) today announced that its confidential, toll-free information line on HIV-related cytomegalovirus ( CMV ) infection is being extended through the end of 1996. In its first six months of operation, the National CMV Prevention Hotli
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
Kaposi s sarcoma, lymphoma, and other malignancies are common in HIV+ individuals. There was no increase in the incidence of Kaposi s sarcoma, lymphoma, or in the progression of cutaneous Kaposi s sarcoma in clinical studies of Serostim. Patients with internal KS lesions were excluded from the studies. Potential effect
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
Continued from PR960822 . . . Hepatic Insufficiency: A reduction in r-hGH clearance has been noted in patients with severe liver dysfunction. However, the clinical significance of this in HIV+ patients is unknown. CLINICAL STUDIES The clinical efficacy of Serostim [somatropin (rDNA origin) for injection] was assessed i
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NORWELL, Mass., Aug. 26 /PRNewswire/ -- For the first time since the AIDS epidemic began, the U.S. Food and Drug Administration ( FDA ) has applied the accelerated review process to a drug which promotes metabolic changes that address the syndrome of AIDS wasting (cachexia), a leading cause of death among people with A
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
SEATTLE, Aug. 23 /PRNewswire/ -- Bailey-Boushay House will receive a $750,000 capital construction fund award from the federal Housing and Urban Development department. The Bailey-Boushay House is one of only 10 sites nation-wide to receive the award front HUD s HOPWA (Housing Organization for People with AIDS) fund.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
BOCA RATON, Fla., Aug. 19 /PRNewswire/ -- NABI (Nasdaq: NABI) today announced the start of an expanded clinical development program for H-BIG(R) (Hepatitis B Immune Globulin [Human] IM 5%), the Company s flagship immunotherapeutic product for prophylaxis of Hepatitis B transmission. Under the program, the Company has i
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, Aug. 19 /PRNewswire/ -- Modifications in the chemical structure of thalidomide by Celgene Corporation (Nasdaq: CELG) have resulted in a novel series of compounds that may be useful for treating a wide range of inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and other condi
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CHICAGO, Ill., Aug. 15 /PRNewswire/ -- Alpha Therapeutic Corporation, Armour Pharmaceutical Company, Baxter Healthcare Corporation and Bayer Corporation announced today that Judge John F. Grady of the United States District Court for the Northern District of Illinois in Chicago has preliminarily approved a settlement a
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WORCESTER, Mass., Aug. 15 /PRNewswire/ -- Hybridon, Inc. (Nasdaq: HYBN) today began a Phase I clinical trial in London of GEM(R)132, which the Company believes is the first advanced chemistry antisense compound administered to humans. This trial represents the first step in Hybridon s two pronged development of GEM132
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
MOUNTAIN VIEW, Calif., Aug. 14 /PRNewswire/ -- Protein Design Labs, Inc. (PDL) announced that the Studies of the Ocular Complications of AIDS (SOCA) group decided today to stop enrollment and treatment in the Phase II/III trial of PDL s PROTOVIR (TM) human anti- CMV antibody (MSL 109) as a supplemental treatment to
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
MORRIS PLAINS, N.J., Aug. 14 /PRNewswire/ -- Immunomedics, Inc. (Nasdaq: IMMU) today announced the issuance of U.S. patent No. 5,541,297, creating new conjugates useful in cancer or infectious disease therapy. The patent extends Immunomedics U.S. patent portfolio to 32 and its foreign equivalents to over 100. The compa
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
LANSING, Mich., Aug. 12 /PRNewswire/ -- Jackson National Life is pleased to report that the U.S. Court of Appeals for the Fifth Circuit has issued a ruling vindicating Jackson National s position in the suit filed by Jody Deramus. Mrs. Deramus brought suit against Jackson National in 1992, accusing it of breaching an a
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CHICAGO, Aug. 7 /PRNewswire/ -- If we cured AIDS, heart disease or cancer, how would it affect life expectancy? A study by Dr. Dejian Lai, of the School of Public Health at the University of Texas, Houston, discussed at the Joint Statistical Meetings (Chicago -- August 3-8) gives some surprising answers. The potential
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NASHVILLE, Tenn., Aug. 7 /PRNewswire/ -- A new study to be published in the August 8, 1996 issue of The New England Journal of Medicine shows clarithromycin (Biaxin(R)) prolongs life by reducing the incidence of Mycobacterium avium complex (MAC) infection in patients with advanced HIV infection. Mark Pierce, M.D., Vand
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
SAN DIEGO, Calif., Aug. 7 /PRNewswire/ -- The University of California, San Diego, today issued the following: According to a study published in today s New England Journal of Medicine, once-weekly dosing of azithromycin is a simpler, more effective regimen than daily rifabutin (2 versus 14 tablets weekly) for the prev
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
COLUMBUS, Ohio, Aug. 7 /PRNewswire/ -- Roxane Laboratories today announced that distribution has begun for VIRAMUNE(R) ( nevirapine ), the first drug in a new class of compounds called non-nucleoside reverse transcriptase inhibitors (NNRTI s). NNRTI s have a unique mechanism of action and a distinct side eff
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, Aug. 6 /PRNewswire/ -- President Bill Clinton today signed into law the first piece of major environmental legislation sent to him by Congress in more than two years. The bill, reauthorizing the Safe Drinking Water Act, was the only environmental legislation to receive strong bipartisan support in Congress
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
ATLANTA and PHILADELPHIA, Aug. 5 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. and SmithKline Beecham (SB) announced today they have established a co-promotion agreement to market SB s Famvir(R) (famciclovir), an antiviral agent that recently received U.S. Food and Drug Administration ( FDA ) clearance for treatment
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
PRINCETON, N.J., Aug. 5 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO, LIPOZ) has received marketing approval for ABELCET(R) (Amphotericin B Lipid Complex Injection) in Greece . The product was approved for the first-line treatment of cryptococcal meningitis, a relatively common fungal
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WHAT: A report calling for higher national standards to protect the nation s blood supply from infectious agents including the hepatitis C and HIV viruses and other blood-borne pathogens. WHO: Released by the House of Representatives Government Reform and Oversight Committee, and hepatitis C recommendations underscored
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CHICAGO, Aug. 5 /PRNewswire/ -- More than 20 studies presented at the recent XI International Conference on AIDS involved the female condom, ranging from a strong supportive discussion by Dr. Christopher Elias of The Population Council at a plenary session, to Dr. Erica Gollub s oral presentation on the encouraging ini
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
SciClone Reports Statistically Significant Response to ZADAXIN Treatment in Meta-analysis of Completed Series of Hepatitis B Clinical Trials SAN MATEO, Calif., Aug 1 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN), an international biopharmaceutical company, today announced its plan to file for regulatory
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, Aug 1 /PRNewswire/ -- What began as a typical weekday morning on a Tokyo subway in March 1995 quickly turned into a disaster as hundreds of commuters were exposed to a deadly vapor, known as sarin gas. This terrorist attack is the largest documented civilian exposure to a warfare nerve agent leading to 12 d
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
LA JOLLA, Calif., July 31 /PRNewswire/ -- LIDAK Pharmaceuticals (Nasdaq-NNM: LDAKA) announced that it has commenced the first of two additional Phase 3 clinical studies in the United States with n- docosanol 10% cream (LIDAKOL(R)) for the topical treatment of recurrent oral herpes (i.e., cold sores or fever blisters).
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
Rep. Tom Coburn, M.D. (R-OK) will announce the introduction of the HIV Prevention Act of 1996 at a press conference to be held Thursday, August 1. Rep. Coburn is a practicing physician and the author of the Baby AIDS law. Rep. Coburn will be joined by Americans for A Sound AIDS/HIV Policy (ASAP), the Independent Women
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
PHILADELPHIA, and SALT LAKE CITY, Utah, July 31 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) and TheraTech, Inc. (Nasdaq: THRT) today announced that Andropatch(TM), a transdermal patch for the treatment of testosterone-deficient, hypogonadal men, has been approved for marketing by the regulatory authorities in the
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
DUBLIN, Ireland , July 30 /PRNewswire/ -- Trinity Biotech plc (Nasdaq: TRIBY) today announced the launch of two new rapid, one step tests for HIV and Hepatitis B. These tests are unique in that they require only one drop of either whole blood, serum or plasma and no other steps to determine the HIV or Hepatitis B statu
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WORCESTER, Mass., and GENEVA, July 30 /PRNewswire/ -- BASF Bioresearch Corporation and Ares-Serono have signed an agreement for BASF to manufacture Ares-Serono s mammalian cell-derived recombinant human growth hormone (hGH) for commercial production, the companies announced today. In April the FDA issued an ap
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, July 24 /PRNewswire/ -- A team of Environmental Protection Agency drinking water experts has been studying the District of Columbia s drinking water system for the last two weeks, and has developed a list of priorities for the District on how to improve drinking water quality. The team was dispatched to the
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
IRVINE, Calif., July 24 /PRNewswire/ -- At the Eleventh Annual International Conference on AIDS held in Vancouver, British Columbia during the second week of July, a number of promising new combination drug treatments were announced that, in some cases, greatly reduce or may potentially eradicate the Human Immune Defic
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
RESEARCH TRIANGLE PARK, N.C., July 23 /PRNewswire/ -- A study to determine the effect of the anti-HIV therapy Epivir (R) (lamivudine; 3TC ) on survival, delay in disease progression or both, has been stopped after an interim analysis of the data showed a 54 percent reduction in the rate of HIV d
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
DENVER, July 24 /PRNewswire/ -- With the introduction of an interactive online HIV/AIDS continuing medical education (CME) program for healthcare professionals, Internet solutions provider Online System Services (Nasdaq: WEBB) has helped to develop and launch a new healthcare industry strategy to deliver vital, real-ti
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CAMBRIDGE, Mass., July 24 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for Vertex s patent application covering VX-478 and related novel HIV protease inhibitors . Vertex
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
EATONTOWN, N.J., JULY 24 /PRNewswire/ -- Roberts Pharmaceutical Corporation (Nasdaq: RPCX) announced today that inventory is in place for the near-term Canadian launch of Advantage 24 (R), a vaginally delivered contraceptive gel. Roberts obtained the exclusive Canadian rights to Advantage 24 from Columbia Laboratories,
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
ALEXANDRIA, Va., July 22 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq: CELI/CELIW) today announces that it has purchased all remaining rights to the HGP-30 AIDS vaccine from Nippon Zeon Company, Ltd. of Japan for 45,000 shares of CEL-SCI common stock. This third and final transaction completes CEL-SCI s plan to bring in
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, July 20 /PRNewswire/ -- The following release was issued today by the Guatemalan Berries Commission: Responding to an alleged connection between Guatemalan raspberries and outbreaks of cyclospora infection in the United States and Canada , we, the Guatemalan berry growers, are cooperating fully with Amer
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, British Columbia, July 11 /PRNewswire/ -- Today, during a presentation at the XI International Conference on AIDS, the Centers for Disease Control and Prevention (CDC) will release a national survey of AIDS policies and education programs in the workplace. This survey revealed that nearly half of American wo
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, British Columbia, July 11 /PRNewswire/ -- Glaxo Wellcome today issued the following: Preliminary data from a small study suggest that treatment of patients with the triple drug combination of Epivir (R) (lamivudine; 3TC )+Retrovir(R) (
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, British Columbia, July 11 /PRNewswire/ -- Glaxo Wellcome today issued the following: Results of a small, open-label study suggest that the combination of Epivir (R) (lamivudine; 3TC )+Retrovir(R) (zidovudine;
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
SAN MATEO, Calif., July 11 /PRNewswire/ -- SciClone Pharmaceuticals, Inc., (Nasdaq: SCLN) today reported that preliminary Phase III data being presented at the 11th International Conference on AIDS in Vancouver, provides further evidence that thymosin alpha 1 can influence the immune system in individuals. The findings
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, Britsh Columbia, July 11 /PRNewswire/ -- HIV-1 quantitation, or viral load, and CD4+T-cell counts, when used in combination, provide the most powerful indicator of risk of AIDS and death in HIV-infected individuals, according to new findings from the Multicenter AIDS Cohort Study (MACS) presented today at th
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, British Columbia, July 11 /PRNewswire/ -- A combination of Abbott Laboratories (NYSE: ABT) Norvir ( ritonavir ) and Hoffmann-LaRoche s Invirase (saquinavir mesylate) reduced HIV RNA by 99.6 percent at six weeks, according to early data presented
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, British Columbia, July 10 /PRNewswire/ -- Research presented today at the XI International Conference on AIDS shows how new therapies aimed at the cellular protein cyclophilin may be instrumental in preventing the human immunodeficiency virus (HIV) from infecting new cells. This finding by The Picower Instit
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, British Columbia, July 10 /PRNewswire/ -- In research presented here today at the 11th International Conference on AIDS, economic modeling based on outcomes data and medical care costs in both the United States and United Kingdom demonstrates that Abbott Laboratories
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, British Columbia, July 10 /PRNewswire/ -- In a panel discussion at the International AIDS Conference today, researchers stress the important link between the treatment of other sexually transmitted diseases and reduction in the spread of HIV. Judith Wasserheit, M.D., M.P.H., cites the results of a community-
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
ENGLEWOOD, Colo., July 10 /PRNewswire/ -- Verex Laboratories, Inc. (OTC BULLETIN BOARD: VRXL) announced that significant new scientific information was released today at the XI International Conference on AIDS in Vancouver, British Columbia, concerning its controlled release AZT formulation, Aztec(R).
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, British Columbia, July 8 /PRNewswire/ -- Madeleine Duvic, MD, Chief of Dermatology at The University of Texas -- Houston Medical School, today reported to the medical scientific community at the XIth International AIDS Conference interim results of Phase I/II clinical trials of ALRT1057 (9-cis-retinoic acid)
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, British Columbia, July 9 /PRNewswire/ -- A triple combination therapy including VIRAMUNE (R)( nevirapine ) demonstrated a sustained twelve month reduction in viral load below the limit of detection in Trial BI ( Boehringer Ingelheim ) 1046, which was presented today at the International AIDS Conf
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, British Columbia, July 9 /PRNewswire/ -- Despite a revolution in sex education since the AIDS epidemic began, the results of the Durex Global Survey(l) released at the XI International Conference on AIDS in Vancouver show that school-based sex education in the U.S. lags far behind other countries as the prim
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CARLSBAD, Calif., and PITTSBURGH, July 9 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) and Bayer Corporation announced today that they have entered into a collaboration agreement to develop a gene therapy product for the treatment of hemophilia A. Bayer Corporation, a market leader in the treatment of
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
FOR: Editors and correspondents covering the 11th International Conference on AIDS, Vancouver, July 7-11, 1996. RE: Current clinical research into new applications of thalidomide (SYNOVIR(TM)) for several major complications of AIDS, including cachexia (or wasting disease, a complication suffered by an estimated
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, Canada , July 8 /PRNewswire/ -- Luis Vicente Giay, President of Rotary International and Peter Piot, Executive Director of the United Nations Programme on HIV/AIDS ( UNAIDS ) today signed an agreement pledging their organizations to work together to save the lives of millions of young people who are at risk
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
HOUSTON, July 8 /PRNewswire/ -- Data will be presented this week at the Eleventh International Conference on AIDS in Vancouver that reinforces the activity and safety of VIRACEPT(TM) (nelfinavir mesylate), when used in combination therapy. Joseph Gathe, M.D., Montrose Clinic - Houston Clinical Research, Houston, presen
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, British Columbia, July 7 /PRNewswire/ -- Issuing an urgent global call to marshall world resources to develop an AIDS vaccine, the International AIDS Vaccine Initiative (IAVI) today announced initial multi-million dollar funding to help accelerate AIDS vaccine research and development worldwide. A vaccine is
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, B.C., July 7 /PRNewswire/ -- Leading AIDS researchers meeting in Vancouver, B.C. on the eve of the official opening of the XI International Conference on AIDS, discussed the growing problem of drug resistance in patients with fungal infections, one of the most common opportunistic infections affecting AIDS p
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, British Columbia, July 8 /PRNewswire/ -- Despite the current AIDS epidemic, the results of a recent global survey released at the XI International Conference on AIDS show that U.S. respondents view taking precautions against AIDS as the least important factor when making love. Among the 10,000 sexually activ
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CAMBRIDGE, Mass., July 8 /PRNewswire/ -- Scientists at LeukoSite Inc., the Dana-Farber Cancer Institute and Children s Hospital have demonstrated that a chemokine coreceptor named CCR3 is used by the AIDS virus to enter and infect certain white blood cells, LeukoSite announced today. The research, reported in the June
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
SAN FRANCISCO, July 8 /PRNewswire/ -- Data presented today at the Eleventh International Conference on AIDS by Marcus Conant, M.D., Conant Medical Group, San Francisco, substantiate the safety and antiviral activity of VIRACEPT(TM) (nelfinavir mesylate), Agouron Pharmaceutical s HIV protease inhibitor. Dr. Conant studi
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
LA JOLLA, Calif., July 8 /PRNewswire/ -- Agouron Pharmaceuticals, Inc., (Nasdaq-NNM: AGPH) today summarized reports of recent results from open label clinical studies of the investigational HIV protease inhibitor VIRACEPT(TM) (nelfinavir mesylate, formerly AG1343). The results include further evidence that VIRACEPT sha
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NEW YORK, July 8 /PRNewswire/ -- Martin Markowitz, M.D., Staff Investigator at The Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York, will present data this week at the Eleventh International Conference on AIDS that confirm undetectable levels of HIV-RNA in plasma as well as negative PBMC c
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, July 8 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) protease inhibitor Norvir ( ritonavir ), in combination with the nucleoside analogues AZT and ddC , sustai
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NEW YORK, July 3 /PRNewswire/ -- Elizabeth Taylor, Founding National Chairman of the American Foundation for AIDS Research ( AmFAR ) and longtime advocate for people with AIDS, will travel to Vancouver to attend the XI International Conference on AIDS. The actress will co- host AmFARs July 8 reception with Dr. Mathilde
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VANCOUVER, B.C., July 3 /PRNewswire/ -- According to a study in this week s issue of The Journal of the American Medical Association (JAMA), a twice-daily dose of Famvir(R) (oral famciclovir, SmithKline Beecham) significantly reduced all symptoms of recurrent genital herpes in immunocompetent patient
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
LANSING, Mich., June 25 /PRNewswire/ -- The Michigan Department of Community Health (MDCH) today issued some early advice for use of a new home blood collection kit that can show whether someone is infected with the virus that causes AIDS. The test may be available in Michigan as early as 1997. More than 99 percent acc
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, June 25 /PRNewswire/ -- Legislators who oppose access to family planning are grossly out of touch with the American people, a new poll reveals. Family planning works to prevent unintended pregnancies and HIV/AIDS, and the American people know it, said Planned Parenthood Federation of America President Glori
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, June 25 /PRNewswire/ -- The American Water Works Association (AWWA) endorses the Safe Drinking Water Act reauthorization bill (H.R. 3604), which was passed by unanimous voice vote in the House today. The bill is unique among the environmental legislation that has been acted upon by the House this year in th
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CHICAGO, June 24 /PRNewswire/ -- In its ongoing effort to monitor HIV issues that affect dentistry, the American Dental Association (ADA) recently took action on both scientific and legal issues. The ADA s council on Scientific Affairs completed a review of recent scientific literature on infection control and reiterat
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
BOCA RATON, Fla., June 24 /PRNewswire/ -- Neozyme II Corporation (Nasdaq: NIIUF) and NABI (Nasdaq: NABI) announced today the halt of their Phase II clinical trial for HyperGAM+(TM)CF (Immune Globulin Intravenous [Human] [Pseudomonas aeruginosa]), for the treatment of severe Pseudomonas lung infections in Cystic Fibrosi
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
MILWAUKEE, June 24 /PRNewswire/ -- In 1993, when hundreds of thousands of Milwaukee residents became ill and a number of deaths resulted from cryptosporidium infected water, Tom Pokorsky s jaw set. Our assumption is that safe drinking water should be a perfectly reasonable expectation, says Pokorsky, president and chie
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
PARIS, June 21 /PRNewswire/ -- Researchers from Europe and the US gathered here today to launch the International Association of Researchers in Cortisol and Anti-Cortisols (IARCA) and present new findings showing the negative causal effect of cortisol in diseases for which current treatments still remain unsatisfactory
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CARLSBAD, Calif., June 18 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it has received a patent from Finland on its core HIV technology. This patent, issued to inventors Jonas Salk, M.D. and Dennis J. Carlo Ph.D., has been licensed to the company and covers The Immune Response Cor
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, June 17 /PRNewswire/ -- On the eve of World Animal Awareness Week, scientists and patient advocates joined forces today to highlight specific areas of research that are currently endangered due to the advancement of the animal rights movement, and its opposition to the use of laboratory animals in all medic
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
SUNNYVALE, Calif., June 17 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today the interim results of a Phase I clinical trial of its photosensitizer lutetium texaphyrin (Lu-Tex). The findings were presented yesterday at the annual meeting of the American Society for Photobiology in Atlanta. The study in
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
Silver Spring, MD -- June 10, 1996 -- The Antiviral Drugs Advisory Committee to the U.S. Food and Drug Administration ( FDA ) on Friday voted to recommend that the agency grant accelerated approval for VIRAMUNE. ( nevirapine ) in combination with nucleoside analogues for treating human immunodeficiency virus (HIV) infe
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CHICAGO, June 6 /PRNewswire/ -- This week, the Food and Drug Administration approved a new test to help determine how fast an individual s infection with HIV is progressing to AIDS. Illinois Masonic Medical Center (IMMC) is the only hospital in the Chicago area and one of the first medical centers in the Midwest to off
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
PHILADELPHIA, June 6 /PRNewswire/ -- Through the direct efforts and collaboration of Thrift for AIDS and the Philadelphia AIDS Consortium, the much needed program providing transportation, Transport for Access, to persons living with HIV and AIDS in the greater Philadelphia area is moving forward. Transport for Access
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NUTLEY, N.J., June 6 /PRNewswire/ -- Prophylaxis with oral Cytovene(R) (ganciclovir capsules) significantly reduces the risk of cytomegalovirus ( CMV ) disease in people with advanced AIDS, according to results of a study published today in The New England Journal of Medicine. A 49 percent reduction in the risk of CM
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
PRINCETON, N.J., June 6 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO and LIPOZ) has received marketing approval for ABELCET(R) (Amphotericin B Lipid Complex Injection) in Sweden . The approved indication is for the treatment of severe, invasive, fungal infections in patients who have not responded to conven
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CRUTTENDEN ROTH, HEALTHCARE GROWTH STOCK CONFERENCE, NEW YORK, June 6 /PRNewswire/ -- Unimed Pharmaceuticals, Inc. (Nasdaq: UMED) President and CEO Stephen M. Simes shared the company s progress on its strategic plan at today s Cruttenden Roth Healthcare Growth Stock Conference. Since the current management began leadi
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
LAS VEGAS, June 5 /PRNewswire/ -- Because his 14-year-old son died of AIDS caused by a tainted blood transfusion, a Veterans Administration doctor says he is working hard to develop what he believes may be a cure for the fatal disease. But life can be funny, and while he was working on an AIDS cure, he says he develope
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WORCESTER, Mass., June 5 /PRNewswire/ -- Alpha-Beta Technology, Inc. (Nasdaq: ABTI) announced today that its scientists in collaboration with researchers at the Worcester Polytechnic Institute, The Center for Blood Research at Harvard Medical School, and the University of California at Irvine, have identified a novel r
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, D.C., June 4 /PRNewswire/ -- As a result of 5,000 interviews conducted in fifteen cities and seven languages, Market Segment Research & Consulting (MSR&C) has released the 1996 MSR&C Ethnic Market Report, the most comprehensive report to date detailing the demographics, consumer behavior, media
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
BRANCHBURG, N.J., June 3 /PRNewswire/ -- The U.S. Food and Drug Administration ( FDA ) today approved for marketing Roche Molecular Systems (RMS) AMPLICOR HIV-1 MONITOR(TM) Test, the first test to accurately and precisely measure quantities of HIV-1 RNA in the blood (viral load ). Using polymerase chain reaction (PCR)
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
ALEXANDRIA, Va., June 3 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq-NNM: CELI) and the University of Nebraska Medical Center today announce the scientific presentation of results obtained with CEL-SCI s HGP-30 AIDS vaccine by Dr. James E. Talmadge of the University of Nebraska. He reported that 78% of SCID mice who had
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
DENVER, May 31 /PRNewswire/ -- Air Methods Corporation (Nasdaq-NNM: AIRM) announced today at a press conference held at 11:30 a.m. EST at the Grand Ballroom, The Plaza Hotel, New York City, that it had acquired a five percent interest in EMX Global Emergency Services ( EMX ), which today launched The EMX Card -- the na
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
DALLAS, May 29 /PRNewswire/ -- Data presented for the first time today suggest that oral ganciclovir (Cytovene(R) capsules) can help prevent potentially life-threatening cytomegalovirus ( CMV ) disease in liver transplant recipients. Data from study GAN 040, Efficacy and Safety of Oral Ganciclovir in the Prevention of
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NEW YORK, May 29 /PRNewswire/ -- Alpha Therapeutic Corporation, Armour Pharmaceutical Company, Baxter Healthcare Corporation and Bayer Corporation, four companies that process and distribute plasma-protein therapies for treatment of hemophilia, announced today that they have made a formal offer of $640 million intended
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
PRINCETON, N.J., May 29 /PRNewswire/ -- New lipid preparations of the mainstay antifungal agent amphotericin B are an important contribution to the treatment of often fatal fungal infections, according to a new report published in a supplement to the May issue of Clinical Infectious Diseases. The authors say these agen
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CARLSBAD, Calif., May 29 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today the start of the first clinical trial in children using REMUNE, an HIV therapy being developed by Immune Response. This Phase I trial, which is being conducted in collaboration with the National Institutes of Health
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CARLSBAD, Calif., May 28 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP), in collaboration with Claire Doerschuk at the Harvard School of Public Health and collaborators at several academic research laboratories, have demonstrated inhibition of intercellular adhesion molecule-1 (ICAM-1) with an antisense oligonucle
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
UNIONDALE, N.Y., May 24 /PRNewswire/ -- Oncogene Science, Inc. (Nasdaq: ONCS) announced today that it has received a Small Business Innovative Research (SBIR) Phase II grant in the amount of approximately $631,000 to identify novel inhibitors of a protein thatis critical to replication of the HIV-1 virus. The principal
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
ABBOTT PARK, Ill., May 24 /PRNewswire/ -- The European Agency for the Evaluation of Medicinal Products (EMEA) has granted within its scientific Committee for Proprietary Medicinal Products (CPMP) a positive scientific opinion on the granting of a European marketing authorization to Abbott s HIV protease inhibitor
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
PITTSBURGH, May 23 /PRNewswire/ -- Viral load, the amount of human immunodeficiency virus (HIV) RNA in the plasma of infected individuals, can accurately predict how quickly people with HIV infection will progress to AIDS and, ultimately, their survival, according to a study published in the May 24, 1996 issue of Scien
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
DETROIT, May 24 /PRNewswire/ -- The following was released by the President s Committee on Employment of People with Disabilities: President Clinton today called for expanding opportunities for every American who is willing to take responsibility for making the most of his or her God-given abilities, and announced his
PR Newswire, 810 Seventh Avenue, New York, NY 10019
CAMBRIDGE, Mass., May 24 /PRNewswire/ -- Cubist Pharmaceuticals, Inc. of Cambridge, Massachusetts has been awarded two separate SBIR Phase II grants to develop antimicrobial agents for the treatment of pneumonia caused by Pneumocystis carinii and for the treatment of Mycobacterium tuberculosis infections. These grants,
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
SAN DIEGO, May 23 /PRNewswire/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that Stephen M. Coutts, Ph.D., the Company s Executive Vice President of R & D, will present data on LJP 394, a drug candidate for lupus, at the International Conference on B Lymphocytes and Autoimmunity held in Prague,
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CARLSBAD, Calif., May 23 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that the United States Patent Office has issued a patent on its licensed gene delivery technology entitled Method for the Introduction of Genes into Mammalian Cells by a Soluble Molecular Complex Comprising a Recepto
PR Newswire, 810 Seventh Avenue, New York, NY 10019
NEEDHAM, Mass., May 23 /PRNewswire/ -- Results from a preclinical study in guinea pigs, conducted with a novel anti-herpes prodrug delivery system developed by DIAD, Inc., were presented today at the Ninth International Conference on Antiviral Research in Japan . In a paper entitled, The Design, Chemistry and Antivira
PR Newswire, 810 Seventh Avenue, New York, NY 10019
NEW YORK, May 22 /PRNewswire/ -- Pharmacia & Upjohn , Inc. (NYSE: PNU), meeting with analysts and investors in New York, today reported on progress in research and development in five core areas -- oncology, central nervous system (CNS), anti-infectives, inflammatory and metabolic diseases. Following the completio
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
NEW ORLEANS, May 22 /PRNewswire/ -- Deficiencies in water treatment and delivery, especially those due to an aging and deteriorating infrastructure, pose serious threats to human health in developed as well as developing countries, according to a report released by the American Academy of Microbiology, A Global Decline
PR Newswire, 810 Seventh Avenue, New York, NY 10019
ALEXANDRIA, Va., May 22 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq-NNM: CELI/CELIW) announces today s presentation of new Tuberculosis (TB) vaccine findings at the American Society of Microbiology meeting in New Orleans. This new data points to the design of a potential TB vaccine/treatment which could be effective ag
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
VERNON HILLS, Ill., May 20 /PRNewswire/ -- Columbia Laboratories, Inc. (AMEX: COB) today announced that the United Nations Global Program on HIV/AIDS ( UNAIDS ) has initiated a major international study to determine the efficacy of Advantage 24(TM), for the prevention of the heterosexual transmission of sexually transm
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
LA JOLLA, Calif., May 20 /PRNewswire/ -- Agouron Pharmaceuticals, Inc., (Nasdaq-NNM: AGPH) today provided updated information concerning the anti-viral activity of its anti-HIV drug VIRACEPT(TM) (nelfinavir mesylate, formerly AG1343) from two pilot Phase II trials. The report on VIRACEPT, an inhibitor of the HIV protea
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
FREMONT, Calif., May 17 /PRNewswire/ -- Rasor Associates, Inc. announced today that it has completed a final phase of its clinical testing of a new disposable medical device -- the Rasor AUTOCAP Safety Needle. The AUTOCAP needle is designed to eliminate needle-stick injuries while maintaining the ease of use of convent
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WASHINGTON, May 16 /PRNewswire/ -- Many different infectious disease agents, previously considered eliminated as major public health problems, are reemerging, according to Stuart B. Levy, M.D., professor of medicine and of molecular biology and microbiology and director of the Center for Adaptation Genetics and Drug Re
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
PHILADELPHIA, May 16 /PRNewswire/ -- HemispheRx Biopharma Inc. (Nasdaq: HEMXU) announced today that Helix Biopharma Corp of British Columbia, Canada , has been authorized to supply Ampligen(R) under the Emergency Drug Release Program of Canada s Health Protection Branch. This authorization means that the drug will beco
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CARLSBAD, Calif., May 16 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) announces results of a comprehensive pharmacokinetic analysis of several second and third generation antisense compounds. These novel compounds are based on the company s proprietary chemistries which enable Isis to design novel antisense comp
PR Newswire, 810 Seventh Avenue, New York, NY 10019
EAST HANOVER, N.J., May 13 /PRNewswire/ -- Sandoz Pharmaceuticals Corporation announced today that it has received clearance to market LAMISIL(R) (terbinafine hydrochloride tablets) TABLETS in the United States , a major advance in the treatment of nail fungal infections (onychomycosis). The only product of its kind, t
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
ABBOTT PARK, Ill., April 24 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) today announced the United States Food and Drug Administration ( FDA ) has cleared for marketing the company s new test for the virus that causes AIDS. The test is intended for the detection of the HIV-1 p24 antigen of the human immunodef
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
SALT LAKE CITY, April 25 /PRNewswire/ -- Marlin Toombs, vice president and director of Medical Discoveries, Inc. (OTC BULLETIN BOARD: MLSC), announced today the successful completion of a series of preliminary studies evaluating MDI-P (Medical Discoveries, Inc. -- Pharmaceutical) as a potential broad spectrum anti-bact
PR Newswire, 810 Seventh Avenue, New York, NY 10019
TAMPA, Fla., April 23 /PRNewswire/ -- An AIDS vaccine made with genetic material from the virus may offer a promising approach to prevent or halt the onset of the deadly disease, said a University of South Florida immunologist working on the investigational vaccine. Preliminary tests at the University of Pennsylvania i
PR Newswire, 810 Seventh Avenue, New York, NY 10019
CARLSBAD, Calif., April 23 /PRNewswire/ -- At the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis of CMV infection, being held in Ft. Myers, Florida, Isis Pharmaceuticals (Nasdaq: ISIP) presented data showing prolonged control of CMV retinitis.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
PITTSBURGH, April 23 /PRNewswire/ -- Stadtlanders Pharmacy, the primary distributor of the newly-approved AIDS protease inhibitor, Crixivan (R), has responded to community concerns regarding cash-paying clients who might have difficulty affording the drug. Stadtlanders has suggested use of a discount drug card program
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
PHILADELPHIA, April 19 /PRNewswire/ -- David S. Shrager is national lead counsel for plaintiffs in the hemophilia litigation for persons infected with the AIDS virus. The following was issued by his office, Shrager, McDaid, Loftus, Flum & Spivey, today: Today s public announcement by the manufacturers of Factor con
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
PITTSBURGH, April 19 /PRNewswire/ -- Bayer Corporation today announced that -- together with three other companies -- it is participating in a settlement proposal for hemophilia patients who contracted HIV through blood-clotting concentrates in the early-to-mid-1980s. Other companies participating in the proposal are B
PR Newswire, 810 Seventh Avenue, New York, NY 10019
WARREN, N.J., April 15 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) said it initiated a Phase II clinical trial of its thalidomide drug Synovir(TM) for the treatment of chronic intractable diarrhea in HIV positive patients. The study has begun enrolling in London with further sites expected to open soon in the U.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
WORCESTER, Mass., April 11 /PRNewswire/ -- Hybridon, Inc. (Nasdaq-NNM: HYBN) today announced the initiation of two new clinical studies of GEM(R) 91, its genetic antisense compound for the treatment of HIV-1 and AIDS. The Company expects to initiate a clinical trial in France later this month to test the bioavailabilit
PR Newswire, 810 Seventh Avenue, New York, NY 10019
CARLSBAD, Calif., April 11 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that the results of the first clinical trial conducted using REMUNE were published in the Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, April 1996. This trial, which began in 1987 with fo
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 9 April 1996
Natural blue pigments are effective antioxidants, recognized disease fighters Food trend: consumers now seek foods that deliver proven health benefits. Can eating Wild Blueberries reduce eyestrain? Control diabetes? Improve circulation? BAR HARBOR, Maine, April 10 /PRNewswire/ -- A new study by researchers at Agricultu
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 9 April 1996
NEW YORK, April 10 /PRNewswire/ -- Sheffield Medical Technologies Inc. (AMEX: SHM) today announced the formation of a new subsidiary, Ion Pharmaceuticals, Inc., and the appointment of Michael Zeldin, Ph.D. as the subsidiary s Chief Executive Officer. Dr. Zeldin, formerly of Cambridge Biomedical Management, brings more
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 9 April 1996
PHILADELPHIA, April 9 /PRNewswire/ -- The Philadelphia AIDS Consortium (AIDS Consortium) took a long needed step yesterday toward healing the internal controversy that has plagued the organization for several years, ensuring that Philadelphia and Southeastern Pennsylvania will continue to receive over $3.1 million in R
PR Newswire - 1 April 1996; 810 Seventh Avenue, New York, NY 10019.
KALAMAZOO, Mich., April 1 /PRNewswire/ -- Pharmacia & Upjohn (NYSE: PNU) announced today that it has begun supplying its anti-HIV investigational drug delavirdine (RESCRIPTOR) to patients in the United States through an expanded access program. Delavirdine
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday, 2 October 1996
NEW YORK, Oct. 2 /PRNewswire/ -- New York-based Melville Biologics, the global leader in the viral inactivation of blood products, today announced it has changed its corporate name to V.I. Technologies, Inc. (VITEX(TM)) to more accurately reflect the company s mission and groundbreaking work in this field. Our company
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 10 April 1996
FERNDALE, Mich., April 10 /PRNewswire/ -- The Midwest AIDS Prevention Project (MAPP) has produced a fast-paced, explicit public service announcement which targets sexually-active young people with HIV prevention information. MAPP will release The Mourning After to broadcast and cable television stations statewide on Th
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - 10 April 1996
HOPKINTON, Mass., April 10 /PRNewswire/ -- Seragen, Inc. (Nasdaq: SRGN) announced today that it has entered into an agreement with Sandoz Pharma, Ltd. of Basel, Switzerland whereby Sandoz will license certain patents from Seragen relating to transplantation treatment. United States
PR Newswire - 2 April 1996; 810 Seventh Avenue, New York, NY 10019.
FOSTER CITY, Calif., April 2 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE) announced today that it has filed an Investigational New Drug application (IND) with the Food and Drug Administration ( FDA ) for a second human clinical trial of the company s gene therapy for AIDS. The trial will test the company s commerc
PR Newswire - 2 April 1996; 810 Seventh Avenue, New York, NY 10019.
WASHINGTON, April 2 /PRNewswire/ -- Researchers at the Johns Hopkins School of Public Health have discovered a gene that may explain how tuberculosis (TB) can survive an immune system attack and lay dormant in its host for years before causing infection. The gene, called sigF, may cause the TB bacteria to sporulate, a
PR Newswire - 1 April 1996; 810 Seventh Avenue, New York, NY 10019.
LOS ANGELES, April 1 /PRNewswire/ -- L.A. Shanti will host a tribute to the late Emmy and Tony Award winning choreographer Michael Peters on Saturday, April 20th, at 8 p.m., in the Wiltern Theatre, 3790 Wilshire Boulevard in Los Angeles. Scheduled to appear are Jamie Lee Curtis, Angela Bassett, Debbie Allen, Sally Kell
PR Newswire - 1 April 1996; 810 Seventh Avenue, New York, NY 10019.
CAMBRIDGE, Mass., April 1 /PRNewswire/ -- International Gene Group, Inc., a subsidiary of IGG International, Inc. (NASD OTC Bulletin Board: IGGI), today announced that researchers from the Chandler Medical Center at the University of Kentucky reported preclinical data suggesting that MMS1 increases survival and immune
PR Newswire - 1 April 1996; 810 Seventh Avenue, New York, NY 10019.
SEATTLE, April 1 /PRNewswire/ -- PATH (Program for Appropriate Technology in Health) an international, nonprofit organization, has collaborated in developing a new technology that will greatly improve the delivery of vaccines in the developing world. HEATmarker(TM), is a vaccine vial label which changes color with expo
PR Newswire - 1 April 1996; 810 Seventh Avenue, New York, NY 10019.
BUFFALO GROVE, Ill., April 1 /PRNewswire/ -- Unimed Pharmaceuticals, Inc. (Nasdaq: UMED) today announced the beginning of a Phase II clinical trial to test the safety and efficiency of its new product, Androgel(TM)-DHT (dihydrotestosterone gel) for treating HIV wasting syndrome and low testosterone levels in AIDS patie
PR Newswire - 28 March 1996; 810 Seventh Avenue, New York, NY 10019.
LOS ANGELES, March 28 /PRNewswire/ -- Our hands are well-known hosts to germs that cause diseases such as common colds and ear infections, food poisoning, pneumonia, hepatitis (type A), skin ailments and wound infections. There is not much we can do to eliminate the source of bacteria spread around us: normal contact w
PR Newswire - 28 March 1996; 810 Seventh Avenue, New York, NY 10019.
SUNNYVALE, Calif., March 28 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the expansion of a Phase I human clinical trial to include the Stanford University Medical Center to evaluate the company s Lu-Tex photosensitizer product as a treatment for various cancers. The study is the first photodynami
PR Newswire - 28 March 1996; 810 Seventh Avenue, New York, NY 10019.
BANGKOK, Thailand and CARLSBAD, Calif., March 28 /PRNewswire/ -- Trinity Medical Group Co., Ltd. of Thailand and The Immune Response Corporation (Nasdaq: IMNR) of the United States , announced today the start of clinical trials, with the first patient in Thailand receiving the REMUNE(TM) treatment (formerly known as th
PR Newswire - 27 March 1996; 810 Seventh Avenue, New York, NY 10019.
LOS ANGELES, March 27 /PRNewswire/ -- National Honorary Co-Chairs Kari Anderson of Pro-Robics in Seattle and Radu Teodorescu of Radu s Physical Culture Studio in New York City, will lead the 8th annual Workout for Hope on April 20, 1996. The event, incorporating more than 20,000 participants, will take place in more th
PR Newswire - 26 March 1996; 810 Seventh Avenue, New York, NY 10019.
CINCINNATI, March 26 /PRNewswire/ -- The Procter & Gamble Company (NYSE: PG) and Roche Holding Ltd. announced today that the second product of the Procter-Syntex joint venture, FEMSTAT(R) 3, an OTC treatment for vaginal yeast infections, is now available nationwide. While all other OTC vaginal yeast infection medic
PR Newswire - 26 March 1996; 810 Seventh Avenue, New York, NY 10019.
BOCA RATON, Fla., March 26 /PRNewswire/ -- The most recent advancements in the research and treatments of AIDS/HIV and the related opportunistic infections will be the focus of a special two-part edition of The Cutting Edge Medical Report. Sponsored by the American Foundation for AIDS Research ( AmFAR ), thes
PR Newswire - 26 March 1996; 810 Seventh Avenue, New York, NY 10019.
RESEARCH TRIANGLE PARK, N.C., March 26 /PRNewswire/ -- Embrex, Inc. (Nasdaq-NMS: EMBX) announced today it was terminating further development effort on its immunomodulator containing avian interleukin 2. In January 1995, the Company announced it had received USDA authorization to manufacture three production lots of it
PR Newswire - 19 March 1996; 810 Seventh Avenue, New York, NY 10019.
PRINCETON, N.J., March 19 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO and LIPOZ) has received approval from the Medicines Control Agency of the United Kingdom to expand the approved indications for ABELCET(TM) to include the first-line treatment of severe, systemic invasive candidiasis. The announcement w
PR Newswire - 22 March 1996; 810 Seventh Avenue, New York, NY 10019.
BRANCHBURG, N.J., March 22 /PRNewswire/ -- Roche Molecular Systems, Inc. announced that the consensus of the Blood Products Advisory Committee of the U.S. Food and Drug Administration ( FDA ) today was to approve their AMPLICOR HIV MONITOR(TM) test as an accurate and precise measure of RNA in the blood. The test revie
PR Newswire - 21 March 1996; 810 Seventh Avenue, New York, NY 10019.
SAN FRANCISCO, March 21 /PRNewswire/ -- Independent, university- based laboratory tests have shown that the world s only self-cleaning, self-sanitizing water filtration system produces tap water that has 63% less bacteria than the water produced by conventional systems operating without the self-cleaning feature. Addit
PR Newswire - 18 March 1996; 810 Seventh Avenue, New York, NY 10019.
BOCA RATON, Fla., March 18 /PRNewswire/ -- The most recent advancements in the research and treatments of AIDS/HIV and opportunistic infections will be the focus of a special two-part edition of The Cutting Edge Medical Report. Sponsored by the American Foundation for AIDS Research ( AmFAR ), these programs feature
PR Newswire - 18 March 1996; 810 Seventh Avenue, New York, NY 10019.
BUFFALO GROVE, Ill., March 18 /PRNewswire/ -- Unimed Pharmaceuticals, Inc. (Nasdaq: UMED) today announced completion of enrollment in its Phase II human clinical trial of nitazoxanide (NTZ) in the treatment of cryptosporidiosis in AIDS patients. The Phase II clinical trial is expected to be concluded by the end of June
PR Newswire - 18 March 1996; 810 Seventh Avenue, New York, NY 10019.
CARLSBAD, Calif., March 18 /PRNewswire/ -- A nationwide clinical trial starts today of a therapy that fights HIV by stimulating the immune system. This is the largest trial of such a treatment ever conducted. Up to 3,000 HIV-infected individuals will participate in this trial testing Remune(TM), a therapy proposed by D
PR Newswire - 18 March 1996; 810 Seventh Avenue, New York, NY 10019.
MARLBOROUGH, Mass., March 18 /PRNewswire/ -- HemaSure Inc. (Nasdaq: HMSR) today announced that it has entered into a definitive cooperation agreement with the German Red Cross ( DRK ) of Springe, Germany , to broaden the worldwide use of methylene blue technology, which is designed to produce safer transfusion plasma.
PR Newswire - 15 March 1996; 810 Seventh Avenue, New York, NY 10019.
PHILADELPHIA, March 15 /PRNewswire/ -- Avid Corporation announced today that it has secured from The DuPont Merck Pharmaceutical Company an exclusive option to license that company s second generation HIV protease inhibitor. The compound, known as DMP 450, has completed Phase I clinical trials. We are pleased to have o
PR Newswire - 15 March 1996; 810 Seventh Avenue, New York, NY 10019.
NORWELL, Mass., March 15 /PRNewswire/ -- Serono Laboratories, Inc., the U.S. affiliate of The Ares-Serono Group, today confirmed ongoing discussions between the company and the U.S. Food and Drug Administration ( FDA ) regarding the New Drug Application (NDA) for Serostim(TM), Serono s mammalian cell-derived recombinan
PR Newswire - 14 March 1996 810 Seventh Avenue, New York, NY 10019.
MIAMI, March 14 -- /PRNewswire/ -- Coulter Corporation announces that they have received a license from the FDA to manufacture and market their new blood screening product, the COULTER(TM) HIV-1 p24 Antigen Assay, which is intended to detect the presence of the p24 Antigen of the HIV-1 virus which causes AIDS. The
PR Newswire - 14 March 1996; 810 Seventh Avenue, New York, NY 10019.
WASHINGTON, March 14 /PRNewswire/ -- The Food and Drug Administration announced today it has granted accelerated approval to the third in a new class of AIDS drugs called protease inhibitors . Indinavir , the new drug, received accelerated approval late yesterday for use alone or in combination with nucl
PR Newswire - 14 March 1996; 810 Seventh Avenue, New York, NY 10019.
WASHINGTON, March 14 /PRNewswire/ -- The Food and Drug Administration today announced the approval of the first antigen test kit to screen blood donors for HIV-1, the virus that is responsible for the vast majority of AIDS cases in the United States . Currently, blood donors are screened with tests that detect HIV anti
PR Newswire - 14 March 1996; 810 Seventh Avenue, New York, NY 10019.
WEST POINT, Pa., March 14 /PRNewswire/ -- The U.S. Food and Drug Administration ( FDA ) has given Merck & Co. , Inc. (NYSE: MRK) clearance to market Crixivan (R) ( indinavir sulfate), an HIV protease inhibitor, under the provisio
PR Newswire - 14 March 1996; 810 Seventh Avenue, New York, NY 10019.
DEERFIELD, Ill., March 13 /PRNewswire/ -- Baxter Ltd., the Japanese subsidiary of Baxter International Inc. (NYSE: BAX), announced today that it has accepted the basic terms of a court-imposed settlement of lawsuits filed by 400 Japanese with hemophilia infected with the AIDS virus from treatment with blood-clotting fa
PR Newswire - 13 March 1996; 810 Seventh Avenue, New York, NY 10019.
PRINCETON, N.J., March 13 /PRNewswire/ -- Data from a randomized, comparative study published in the February issue of Clinical Infectious Diseases, demonstrated that ABELCET(TM) (amphotericin B lipid complex) is less toxic than amphotericin B in the treatment of patients with AIDS-associated cryptococcal meningitis.
PR Newswire - 13 March 1996; 810 Seventh Avenue, New York, NY 10019.
WEST BRIDGEWATER, Mass., March 13 /PRNewswire/ -- Boston Biomedica, Inc. (BBI), announced today that it has filed patent applications for compounds its research has shown to have significant anti-AIDS activity in laboratory studies. The company is seeking patents for compounds discovered to inhibit replication of the H
PR Newswire - 13 March 1996; 810 Seventh Avenue, New York, NY 10019.
ALEXANDRIA, Va., March 13 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq: CELI, CELIW) and University of Nebraska Medical Center today announced promising results from a booster immunization clinical study with the HGP-30 AIDS immunogen. Five (5) out of five (5) volunteers tested who had been vaccinated with CEL-SCI s imm
PR Newswire - 8 March 1996; 810 Seventh Avenue, New York, NY 10019.
PALM SPRINGS, Calif., March 8 /PRNewswire/ -- HemispheRx Biopharma (Nasdaq: HEMXU) reported today at the University of California s Fourth Annual Frontiers of HIV Therapy conference new laboratory and clinical evaluations of the Theta Switch theory as an important immunological mechanism of long-term survival in HIV-in
PR Newswire - 8 March 1996; 810 Seventh Avenue, New York, NY 10019.
SAN MATEO, Calif., March 8 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN), announced that one of its clinical investigators, Dr. YF Liaw, Head of the Liver Unit at Chang Gung Memorial Hospital, presented today an interim report of patient data from his study site showing statistically significant respons
PR Newswire - 7 March 1996; 810 Seventh Avenue, New York, NY 10019.
CAMDEN, N.J., March 7 /PRNewswire/ -- Bishop James T. McHugh, Catholic bishop of the Diocese of Camden, issued the following statement today, the day after a federal appeals court struck down a Washington state ban on physician-assisted suicide. The decision of the U.S. Appeals Court in California is a tragic and dange
PR Newswire - 6 March 1996; 810 Seventh Avenue, New York, NY 10019.
WARREN, N.J., March 6 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) said it began dispensing its experimental thalidomide drug Synovir(TM) under an expanded access protocol approved late last year by the US FDA . The drug is being supplied for treatment of cachexia, a severe wasting condition in AIDS patients.
PR Newswire - 5 March 1996; 810 Seventh Avenue, New York, NY 10019.
WASHINGTON, March 5 /PRNewswire/ -- With one in four new HIV infections in the U.S. occurring among people under the age of 20 -- an average of one every hour -- the White House Office of National AIDS Policy today released a report to the President calling for action by all sectors of society to reverse these troublin
PR Newswire - 5 March 1996; 810 Seventh Avenue, New York, NY 10019.
WASHINGTON, March 5 /PRNewswire/ -- The Family Research Council issued the following: A White House report issued today shows that 25 percent of Americans who are infected with AIDS each year are under the age of 20. The report calls for more explicit AIDS education, and HIV testing without parental notice. This is a p
PR Newswire - 5 Mar 1996; 810 Seventh Avenue, New York, NY 10019.
NUTLEY, N.J., March 5 /PRNewswire/ -- The U.S. Food and Drug Administration ( FDA ) today granted marketing clearance for Vitrasert (TM), an intraocular implant which delivers ganciclovir directly to the eye, for treatment of cytomegalovirus (
PR Newswire - 1 Mar 1996; 810 Seventh Avenue, New York, NY 10019.
MARSHFIELD, Wis., March 1 /PRNewswire/ -- Scientific investigators at the National Farm Medicine Center (NFMC) have discovered a way to efficiently concentrate the intestinal parasites Cryptosporidium and Giardia from large amounts of water. The discovery of this improved method may control outbreaks caused by these pa
VIENNA, Va., Feb. 29 /PRNewswire/ -- The following was issued by America Online (Nasdaq-NNM: AMER): WHAT: Each week America Online s News Channel conducts an online news survey to measure the opinions of AOL members on current events and the issues that effect them. This week, over 20,000 members voted on a survey abou
NUTLEY, N.J., Feb. 29 /PRNewswire/ -- Preliminary data released today at the FDA antiviral advisory committee meeting suggests that 85 to 90 percent of people taking INVIRASE(TM) (saquinavir mesylate) for one year will still be sensitive to ritonavir and
NUTLEY, N.J., Feb. 28 /PRNewswire/ -- The Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration ( FDA ) unanimously recommended the full approval of HIVID(R) (zalcitabine), also known as ddC , for use in combination with AZT (zidovudine
WASHINGTON, Feb. 28 /PRNewswire/ -- The Agency for Health Care Policy and Research today launched its World Wide Web site, making available a wealth of practical, science-based health care information in one convenient place. The AHCPR page joins other HHS agencies on the web, providing easy access to health informatio
PRINCETON, N.J., Feb. 28 /PRNewswire/ -- Striking new results from the largest controlled pediatric trial to date show that Bristol-Myers Squibb s VIDEX (didanosine; ddI) delays progression of AIDS and may be superior to AZT (zidovudine) monotherapy, Bristol-Myers Squibb announced today. The new data from the AIDS Cli
NUTLEY, N.J., Feb. 28 /PRNewswire/ -- Hoffmann-La Roche Inc., today announced that, in partnership with Abbott Laboratories (NYSE: ABT) of North Chicago, Illinois, it will conduct a clinical trial of the Roche protease inhibitor Invirase (TM) (saquinavir) in combination with the Abbott protease
WASHINGTON, Feb. 28 /PRNewswire/ -- Glaxo Wellcome today issued the following statement: Glaxo Wellcome scientists and clinical researchers have been at the forefront of the movement toward combination drug therapy for HIV and AIDS dating back to the late 1980s. The data presented today are limited to a comparison of t
WHAT: The presentation of new study data before the FDA Antiviral Drugs Advisory Committee. The data show that VIDEX(R) (didanosine, ddI), alone or in combination with AZT for treatment of HIV infection, delays progression of disease and prolongs patient survival. In fact, VIDEX alone is just as effective, and in some
CARLSBAD, Calif., Feb. 27 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that its HIV treatment Remune(TM), formerly known as the HIV-1 Immunogen, has received clearance from the Food and Drug Administration to begin a large-scale Phase III clinical endpoint trial. This clinical trial is
NORWELL, Mass., Feb. 27 /PRNewswire/ -- More than 800 people with AIDS wasting have received Serostim(TM), Serono Laboratories mammalian cell-derived recombinant human growth hormone (r-hGH[m]), through a Treatment Investigational New Drug (TIND) access program authorized by the U.S. Food and Drug Administration (
RIDGEFIELD, Conn., Feb. 27 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc., today announced it has submitted a new drug application (NDA) for its non-nucleoside reverse transcriptase inhibitor, VIRAMUNE(R) ( nevirapine ). VIRAMUNE(R) is the first of a new class of antivirals to be submitted to th
HARRISBURG, Pa., Feb. 22 /PRNewswire/ -- Pennsylvania State Public Welfare Secretary Feather O. Houstoun today announced that her department has added the drug Invirase to its arsenal in treating people with HIV disease and AIDS. Invirase (saquinavir mesylate) belongs to a new class of drugs called
CARLSBAD, Calif., Feb. 21 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that the Food and Drug Administration ( FDA ) has given clearance for the release of its HIV-1 Immunogen, to be named Remune(TM), manufactured by the company for use in planned clinical trials. Immune Response has d
CARLSBAD, Calif., and BASEL, Switzerland , Feb. 21 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) and Ciba-Geigy Limited announced they have finalized an agreement to significantly expand their antisense collaboration to include a broad program in antisense research and the development of two promising anticancer
HAYWARD, Calif., Feb. 21 /PRNewswire/ -- Aradigm Corp. today announced that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration for a Phase I clinical trial for systemic pulmonary delivery of morphine. The studies are designed to assess the pharmacokinetics, pharmacodyn
DUBLIN, Ireland , Feb. 20 /PRNewswire/ -- Trinity Biotech plc (Nasdaq: TRIBY) today announced that is has made initial shipments of SeroCard and SalivaCard HIV rapid tests to China and India . Trinity has signed distribution agreements which call for first yea
TAMPA, Fla., Feb. 15 /PRNewswire/ -- A quick, relatively inexpensive genetic test for HIV improves physicians ability to diagnose or rule out HIV infection in newborns whose mothers carry the AIDS virus, a comprehensive University of South Florida study has shown. The commercially available test, using a polymerase cha
MIAMI, Feb. 12 /PRNewswire/ -- Coulter Corporation announces that they have received an approvable letter from the FDA for a new blood screening product, the COULTER(TM) HIV-1 p24 Antigen Assay, which is intended to detect the presence of the p24 antigen of the HIV-1 virus which causes AIDS. Coulter expects final appro
CHICAGO, Feb. 8 /PRNewswire/ -- Both the American Dental Association (ADA) and Centers for Disease Control and Prevention (CDC) recommend that dentists use heat sterilization and universal precautions as the best means to help ensure that patients receive safe dental care. In 1994, the ADA launched a consumer education
CARLSBAD, Calif., Feb. 8 /PRNewswire/ -- Isis Pharmaceuticals (Nasdaq: ISIP) announced it has been issued a composition of matter patent covering a family of novel antisense backbone modifications that can be used to completely replace the phosphodiester or phosphorothioate backbone of an antisense compound. Antisense
OLYMPIA, Wash., Feb. 7 /PRNewswire/ -- The following was released today by the Washington State Department of Health: AIDS now is growing more rapidly among women than men. The state Department of Health offers a hotline and three publications to help women cope with the challenges of living with a disease that has lar
CARLSBAD, Calif., Feb. 7 /PRNewswire/ -- Isis Pharmaceuticals , Inc. (Nasdaq: ISIP), today reported its financial results for the year and for the fourth quarter ended December 31, 1995. For the full year, Isis net loss totaled $23.7 million, or $1.10 per share, compared with a net loss of $18.2 million, or $0.93 per s
CARLSBAD, Calif., Feb. 7 /PRNewswire/ -- The Immune Response Corporation (Nasdaq-NNM: IMNR) announced today that the Australian Patent Office has issued a patent on its licensed gene delivery technology entitled Targeting Viruses and Cells for Selective Internalization by Cells. This patent, #660,629, covering technolo
WASHINGTON, Feb. 1 /PRNewswire/ -- Preliminary results from an ongoing, larger study with Merck s investigational protease inhibitor Crixivan (R)(A) ( Indinavir sulfate) in triple combination with two other AIDS medications showed that levels of HIV in the bloodstream were reduced to levels belo
PRINCETON, N.J., Feb. 1 /PRNewswire/ -- Results of a worldwide clinical trial demonstrate the clinical benefit of the combination of VIDEX(R) (didanosine, ddI) with AZT in treating human immunodeficiency virus, the virus that causes AIDS. The results of the European and Australian Delta Trial, which were announced toda
SAN FRANCISCO, Feb. 1 /PRNewswire/ -- Kaiser Permanente Northern California today announced that it will adopt a model for the basic elements of HIV care suggested by the Community Consortium, a group of more than 200 health care providers who care for the majority of patients with HIV disease in the San Francisco Bay
WASHINGTON, Feb. 1 /PRNewswire/ -- In striking new research presented today, mortality was reduced by approximately one-half among advanced AIDS patients who received Abbott Laboratories (NYSE: ABT) experimental HIV protease inhibitor ritonavir for up to seven months, compared to those who received placebo. The findin
WASHINGTON, Feb. 1 /PRNewswire/ -- Hoffmann-La Roche Inc., the first company to develop and gain marketing clearance (December 6, 1996) for a protease inhibitor, Invirase (TM) (saquinavir mesylate), is leading the shift in HIV treatment strategy being discussed at the Third Conference on Retroviruses and Opportunistic
WASHINGTON, Feb. 1 /PRNewswire/ -- New data presented at the Third Conference on Retroviruses and Opportunistic Infections strongly support the use of oral Cytovene(R) (ganciclovir capsules) for the prevention of cytomegalovirus ( CMV ) disease in people infected with HIV. The data -- the latest from Syntex study 1
PITTSBURGH, Feb. 1 /PRNewswire/ -- Biocontrol Technology, Inc. (Nasdaq: BICO) announced today that its subsidiary, IDT, Inc., in conjunction with HemoCleanse, Inc. of West Lafayette, Indiana, has been granted Food and Drug Administration ( FDA ) approval to conduct expanded studies of whole-body extracorporeal hyperthe
NEW YORK, Jan. 31 /PRNewswire/ -- The American Jewish Congress today called the action of health officials in Israel to discard blood donations from Ethiopians because of fears of HIV virus contamination an appalling mistake but one which was made in good faith in recognition of the lethal nature of AIDS and the absolu
WEST POINT, Pa., Jan. 31 /PRNewswire/ -- Merck & Co. , Inc. (NYSE: MRK) today announced it has submitted to the U.S. Food and Drug Administration ( FDA ) a New Drug Application for Crixivan (R) ( Indinavir sulfate), an investigat
WEST POINT, Pa., Jan. 31 /PRNewswire/ -- Merck & Co. , Inc. (NYSE: MRK) today announced it has submitted to the U.S. Food and Drug Administration ( FDA ) a New Drug Application for Crixivan (R) ( Indinavir sulfate), an investigat
CHICAGO, Jan. 31 /PRNewswire/ -- The Journal of the American Medical Association (JAMA) and Glaxo Wellcome Inc. (Nasdaq: GLX) today announced the creation of a World Wide Web site featuring a collection of peer- reviewed HIV/AIDS information and other resources for health care professionals and the public.
FOSTER CITY, Calif., Jan. 31 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE) announced today that preliminary results reported for the company s Phase I trial of AIDS gene therapy show no treatment-related safety problems. In the treatment arm of the study, individual patients received escalating single doses of huma
NEW YORK, Jan. 30 /PRNewswire/ -- Scientists at the New York Blood Center (NYBC) today announced their discovery of a milk-based compound that in laboratory experiments blocks HIV virus transmission in human cells. The effectiveness of the chemically modified milk protein and its low production cost suggest that the co
PHILADELPHIA, Jan. 30 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) today announced that it has been awarded a contract by the U.S. Centers for Disease Control and Prevention (CDC) to supply Havrix(R)(Hepatitis A Vaccine, Inactivated), the world s first vaccine for hepatitis A, manufactured by SmithKline Beecham Biolo
CHICAGO, Jan. 30 /PRNewswire/ -- The following is a statement from The American Society for Sports Medicine on HIV and other blood-borne pathogens in sports. In light of Earvin Magic Johnson s return to the NBA, the American Orthopaedic Society for Sports Medicine (AOSSM) has received numerous inquiries about HIV-infec
WASHINGTON, Jan. 30 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) today released the following: The experimental HIV protease inhibitor ritonavir, in combination with the nucleoside analogues AZT and ddC , demonstrated potent antiviral activity agains
WASHINGTON, Jan. 30 /PRNewswire/ -- Patients taking Crixivan (R) ( Indinavir sulfate), Merck s investigational protease inhibitor, in combination with two other AIDS medications achieved reductions in the level of HIV in the bloodstream, according to a new open-label study presented here today a
LA JOLLA, Calif., Jan. 30 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. (Nasdaq-NNM: AGPH) today reported that it has initiated pivotal phase II/III clinical trials of the anti-HIV drug VIRACEPT(TM) (nelfinavir mesylate, formerly AG1343). The company said that the multi-center pivotal clinical trials to be carried out
WASHINGTON, D.C., Jan. 29 /PRNewswire/ -- The following was released today by SmithKline Beecham: A clinical trial conducted with oral famciclovir demonstrated the antiviral drug to be safe, well tolerated, and effective in significantly reducing recurrent genital herpes in HIV-infected persons. The findings were prese
RIDGEFIELD, Conn., Jan. 29 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals Inc. today announced it will establish the expanded access program for people with AIDS. VIRAMUNE(R) is an investigational drug that belongs to a new class of anti-retroviral compounds called non-nucleoside reverse transcriptase inhibitors.
WASHINGTON, Jan. 29 /PRNewswire/ -- Exciting results from new studies with Crixivan (R) ( Indinavir sulfate), Merck s investigational protease inhibitor, could change the way doctors treat HIV disease and AIDS, according to a major presentation to leading AIDS researchers at the Third Conferenc
WASHINGTON, Jan. 26 /PRNewswire/ -- Responding to reports that Congress and the White House have agreed to budget deals that endanger the lives and health of millions of Americans, Planned Parenthood Federation of America (PPFA) Interim President Jane Johnson issued the following statement: While Planned Parenthood rec
WHO: Richard Pollard, M.D. Professor of Internal Medicine, Microbiology and Immunology, and Pathology University of Texas Medical Branch at Galveston (Dr. Pollard is the lead investigator for the study) WHAT: A presentation of the interim results of Bristol-Myers Squibb Study Al 460-001, which examines the safety and
PALMETTO, Fla., Jan. 26 /PRNewswire/ -- Early results from the grassroots clinical trial currently underway in the United States to evaluate SPV-30, an extract of the boxwood evergreen tree, as an all natural antiretroviral* and an HIV/AIDS* fighter are encouraging, David Stokes reported here today. Mr. Stokes is coor
BEAVERTON, Ore., Jan. 25 /PRNewswire/ -- Epitope, Inc. (AMEX: EPT) today reported a net loss of $0.13 per share ($1.7 million) for the first quarter of fiscal 1996, ended December 31, 1995, compared with a net loss of $0.39 a share ($4.3 million) for the first quarter of fiscal 1995. Revenue for the quarter totaled $1.
SAN FRANCISCO, Jan. 25 /PRNewswire/ -- It s the one dirty secret left in America. Here, in a land where anything is discussed on television, people are often reluctant to admit that they smoke cigarettes -- and many find that their health care providers are just as reluctant to ask them whether and how often they light
MOUNTAIN VIEW, Calif., Jan. 24 /PRNewswire/ -- Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI) today announced that it has been issued a fundamental patent by the European Patent Office that covers most humanized monoclonal antibodies. This is a highly significant event for PDL and PDL s scientists, said Laurence Jay Ko
DURHAM, N.C., Jan. 24 /PRNewswire/ --Triangle Pharmaceuticals today announced it has entered into an option agreement with Mitsubishi Chemical Corporation under which Triangle will develop MKC-442, Mitsubishi s novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV disease. Mitsubishi will contri
HOUNSLOW, England, Jan. 24 /PRNewswire/ -- Bristol-Myers Squibb s (NYSE: BMY) latest HIV therapy, ZERIT(R) ( stavudine , d4T ), has received a positive opinion from the European Union s Committee for Proprietary Medicinal Products (CPMP*). The CPMP s decision was based on demonstrated proof o
THE WOODLANDS, Texas, Jan. 23 /PRNewswire/ -- Aronex Pharmaceuticals, Inc. (Nasdaq: ARNX) announced today the start of a Nystatin(LF) Phase III multi-center comparative trial, to be conducted at 20 medical centers throughout the U.S. The trial will evaluate Nystatin(LF) for the treatment of life threatening fungal infe
NEW YORK, Jan. 9 /PRNewswire/ -- Since her very public admission at the Republican National Convention in 1991 that she is HIV positive, Mary Fisher has taken an aggressive role in the fight against AIDS. Through her writings and speeches, she has shared her own struggle with millions. Already the author of Sleep With
WASHINGTON, Jan. 17 /PRNewswire/ -- Early analysis of data from clinical trials of a new class of anti-HIV drugs appears to validate the reliability of a tool the medical community has long sought -- a surrogate marker that is highly predictive of the clinical progression of HIV disease. The data come from two, large,
CHICAGO, Jan. 13 /PRNewswire/ -- One public service lawyer, four private lawyers and the United States Attorney General are the 1995 recipients of the John Minor Wisdom Public Service and Professionalism Awards. The awards were announced at a luncheon today during the American Bar Association s Section of Litigation An
PHILADELPHIA, Jan. 11 /PRNewswire/ -- On the eve of the birthday-anniversary of the Rev. Martin Luther King, Jr., the Philadelphia Bar Foundation today announced the distribution of over $400,000 to 32 different law-related public service agencies in the city. The grants will help the indigent, the homeless, the disabl
COSTA MESA, Calif., Jan. 11 /PRNewswire/ -- Allied Biotechnology International, Inc. (ADBI) (OTC BULLETIN BOARD: ADBI) and Allied Biotechnology Latinoamerica (ABL) are pleased to introduce the company s diagnostic products to Latin America. The first products scheduled for distribution feature Over the Counter Tests, i
ITHACA, N.Y., Jan. 10 /PRNewswire/ -- Paracelsian (Nasdaq: PRLN) and the National Cancer Institute (NCI) division of the NIH have entered into a letter of intent to collaborate on extensive studies of its lead compound, PN355, and related compounds as possible treatments for cancer and human immunodeficiency virus (HIV
HAMBRECHT & QUIST HEALTH CARE CONFERENCE, SAN FRANCISCO, Jan. 10 /PRNewswire/ -- Dr. Stephen A. Sherwin, chairman and chief executive officer of Cell Genesys, Inc. (Nasdaq: CEGE) in Foster City, Calif., presented an overview of Cell Genesys yesterday at the 1996 Hambrecht and Quist Life Sciences Conference in San F
HAMBRECHT & QUIST HEALTH CARE CONFERENCE, SAN FRANCISCO, Jan. 9 /PRNewswire/ -- Targeted Genetics Corporation is a presenter at the 1996 Hambrecht & Quist 14th Annual Health Care Conference: Targeted Genetics Corporation (Nasdaq: TGEN), a Seattle-based gene and cell therapy company, initiated four clinical tria
WORCESTER, Mass., Jan 9 /PRNewswire/ -- Cambridge Biotech Corporation today announced that the United States Bankruptcy Court for the District of Massachusetts (Western Division) has declared a non- exclusive patent license to be in effect between Institut Pasteur and Cambridge Biotech as of January 1, 1996, covering C
WASHINGTON, Jan. 9 /PRNewswire/ -- A combination of two antiviral drugs is more effective than either drug alone for controlling recurrences of a blinding eye infection common in people with AIDS, according to new clinical trial results from a Federally-sponsored study. In today s Archives of Ophthalmology, researchers
Jan. 9 /PRNewswire/ -- State Superintendent of Public Instruction Judith Billings has scheduled a news conference to release findings of the most recent survey of health-related behaviors of youth in Washington. The 1995 Adolescent Health Behaviors Survey, the fourth of its kind, will be discussed by Billings as well a
HAMILTON, Mont., Jan. 9 /PRNewswire/ -- Ribi ImmunoChem Research, Inc. announced today that it has completed a license and supply agreement covering the use of Ribi adjuvants in cancer vaccines under development by SmithKline Beecham s vaccine group, SmithKline Beecham Biologicals. Under the license/supply agreement, R
PRINCETON, N.J., Jan. 9 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq: LIPO & LIPOZ) reported that its fourth quarter sales of ABELCET(TM) (Amphotericin B Lipid Complex Injection) increased significantly over the third quarter. At a meeting of investment analysts sponsored by Hambrecht & Quist, L.L.P., Cha
HAMBRECHT & QUIST HEALTH CARE CONFERENCE, SAN FRANCISCO, Jan. 9 /PRNewswire/ -- ClinTrials Research is a presenter at the 1996 Hambrecht & Quist 14th Annual Health Care Conference: ClinTrials Research Inc. (Nasdaq: CCRO) is a global provider of clinical research services to pharmaceutical, biotechnology and med
HAMBRECHT & QUIST HEALTH CARE CONFERENCE, SAN FRANCISCO, Jan. 9 /PRNewswire/ -- U.S. Bioscience is a presenter at the 1996 Hambrecht & Quist 14th Annual Health Care Conference: 1995 was a very important year for U.S. Bioscience, with many critical milestones having been achieved. The company s presentation at t
MENLO PARK, Calif., Jan. 9 /PRNewswire/ -- VidaMed, Inc. (Nasdaq: VIDA) announced today that it has commenced a retained search for a new President and Chief Executive Officer to replace Stuart D. Edwards, who will remain a member of VidaMed s Board of Directors. The Board of Directors has appointed a CEO Search Commit
SAN FRANCISCO, Jan. 8 /PRNewswire/ -- With more than 150 products in late-stage clinical trials, the biotechnology industry is poised to continue the strong performance that made the sector the outstanding market performer of 1995, investors at the nation s largest healthcare conference were told today. We expect to se
SAN FRANCISCO, Jan. 8 /PRNewswire/ -- Today, CHRONIMED Inc. (Nasdaq: CHMD) presented to investors at the Hambrecht and Quist 14th Annual Healthcare Conference. CHRONIMED is a diversified healthcare company serving patients with chronic diseases. Seventy-five percent of healthcare spending in the United States
CAMBRIDGE, Mass., Jan. 8 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it earned milestone and option fees totaling $5.0 million from Glaxo Wellcome (NYSE: GLX) and Kissei Pharmaceutical Co., Ltd. at the end of 1995. The payments are related to the development and commercializa
MOUNTAIN VIEW, Calif., Jan. 8 /PRNewswire/ -- Protein Design Labs, Inc., (PDL) (Nasdaq: PDLI) announced today a collaboration with a Japanese pharmaceutical company under which PDL will humanize a mouse monoclonal antibody for potential use in treating certain infectious diseases. PDL has been paid a signing fee and ca
SAN DIEGO, Jan. 5 /PRNewswire/ -- Ligand Pharmaceuticals Inc. (Nasdaq: LGND) today announced interim results of Phase I/II human clinical trials of Targretin(TM) (LGD1069) Topical in Cutaneous T-cell Lymphoma (CTCL or Mycosis Fungoides) and Kaposi s sarcoma (KS). The data to be presented at 8 a.m. Monday Pacific Standa
STAMFORD, Conn., Jan. 5 /PRNewswire/ -- VIMRx Pharmaceuticals Inc. (Nasdaq SmallCap: VMRX (common stock), VMRXW (warrants)) announced today that it has received final approval from the Thailand FDA to proceed with the clinical trial to evaluate its antiviral agent, VIMRxyn (synthetic hypericin), in HIV-infected patient
PRINCETON, N.J., Jan. 4 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration ( FDA ) today granted full marketing clearance to ZERIT(R) ( stavudine , d4T ), a nucleoside analo
ALEXANDRIA, Va., Jan. 4 /PRNewswire/ -- CEL-SCI CORPORATION (Nasdaq-NNM: CELI/CELIW) announced today that it has acquired a new patented medical technology which directs the body to choose a specific immune response. This new T-cell Modulation Process using heteroconjugates was acquired from CELL MED, Inc. of Columbia,
NORTH MIAMI, Fla., Jan. 3 /PRNewswire/ -- Total Medical Compliance, Inc., a South Florida health industry consulting company, announced today it has been named the state and federal compliance consultant for all 34 PCA Family Medical Centers throughout Florida. Under the terms of the contract, TMC will conduct staff tr
WELLESLEY, Mass., Jan. 3 /PRNewswire/ -- Ampersand Ventures (Ampersand) today announced that it has invested $5 million in Melville Biologics, Inc. (Melville), a leading supplier of virally inactivated blood products. A spinoff from the New York Blood Center (NYBC), Melville was established in February 1995 to commerci
CAMBRIDGE, Mass., Jan. 2 /PRNewswire/ -- After two years of gloom and doom in the wake of product disappointments, entrepreneurial biotechnology clearly established itself in 1995 as the unrivaled supplier of new products and technology to the pharmaceutical industry. Investors responded to this strong confirmation of
ITHACA, N.Y. AND SEATTLE, Jan. 2 /PRNewswire/ -- Paracelsian, Inc. (Nasdaq: PRLN) today announced the initiation of Phase I clinical trials of its primary compound, PN355, for the treatment of HIV-1, the virus that causes AIDS. The trials will be conducted at Bastyr University in Seattle, one of the world s leading cen
PR Newswire, 810 Seventh Avenue, New York, NY 10019 -
CHICAGO, Aug. 2 /PRNewswire/ -- The following release was issued today by Viaticus Inc.: A major provision in the health insurance bill passed today by Congress represents a landmark development that will benefit millions of Americans with chronic and life-threatening illnesses. President Clinton is expected to sign th
This information is designed to support, not replace, the relationship that exists between you and your doctor.